



Clinical Benefits and Safety of FMS-Like Tyrosine Kinase 3 Inhibitors in Various Treatment Stages of Acute Myeloid Leukemia: A Systematic Review, Meta-Analysis, and Network Meta-Analysis

OPEN ACCESS

Edited by:

Adrián Mosquera Orgueira, University Hospital of Santiago de Compostela, Spain

Reviewed by:

Claudio Cerchione, Istituto Scientifico Romagnolo per lo Studio e il Trattamento dei Tumori (IRCCS), Italy Manuela Piazzi, National Research Council (CNR), Italy Bruno Quesnel, Centre Hospitalier Regional et Universitaire de Lille, France

> *Correspondence: Li Yu

yuli@szu.edu.cn

Specialty section:

This article was submitted to Hematologic Malignancies, a section of the journal Frontiers in Oncology

Received: 26 March 2021 Accepted: 11 May 2021 Published: 03 June 2021

Citation:

Xu Q, He S and Yu L (2021) Clinical Benefits and Safety of FMS-Like Tyrosine Kinase 3 Inhibitors in Various Treatment Stages of Acute Myeloid Leukemia: A Systematic Review, Meta-Analysis, and Network Meta-Analysis. Front. Oncol. 11:686013. doi: 10.3389/fonc.2021.686013 Qingyu Xu^{1,2}, Shujiao He¹ and Li Yu^{1*}

¹ Department of Hematology and Oncology, International Cancer Center, Shenzhen Key Laboratory, Shenzhen University General Hospital, Shenzhen University Clinical Medical Academy, Shenzhen University Health Science Center, Shenzhen, China, ² Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

Background: Given the controversial roles of FMS-like tyrosine kinase 3 inhibitors (FLT3i) in various treatment stages of acute myeloid leukemia (AML), this study was designed to assess this problem and further explored which FLT3i worked more effectively.

Methods: A systematic review, meta-analysis and network meta-analysis (NMA) were conducted by filtering PubMed, Embase, Cochrane library, and Chinese databases. We included studies comparing therapeutic effects between FLT3i and non-FLT3i group in AML, particularly *FLT3*(+) patients, or demonstrating the efficiency of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in *FLT3*(+) AML. Relative risk (RR) with 95% confidence intervals (CI) was used for estimating complete remission (CR), early death and toxicity. Hazard ratio (HR) was used to assess overall survival (OS), event-free survival (EFS), relapse-free survival (RFS) and cumulative incidence of relapse (CIR).

Results: After addressing all criteria, 39 studies were eventually analyzed. Better CR was accomplished by FLT3i in untreated AML (RR 0.88, p = 0.04) and refractory and relapsed *FLT3*(+) AML (rrAML) (RR 0.61, p < 0.01) compared to non-FLT3i arm, followed by improved survival (untreated AML: OS, HR 0.76; EFS, HR 0.67; RFS, HR 0.72; all p < 0.01; *FLT3*(+) rrAML: OS, HR 0.60, p < 0.01; RFS, HR 0.40, p = 0.01). In addition, allo-HSCT improved survival in *FLT3*(+) AML (OS, HR 0.53; EFS, HR 0.50; RFS, HR 0.57; CIR, HR 0.26; all p < 0.01), which was further prolonged by FLT3i administrated after allo-HSCT (OS, HR 0.45; RFS, HR 0.34; CIR, HR 0.32; all p < 0.01). Additionally, FLT3i consistently improved OS (p < 0.05) regardless of *FLT3-ITD* ratio, when compared to non-FLT3i group. Besides, FLT3i showed significantly increased risk of thrombocytopenia, neutropenia, anemia, skin- and cardiac-related adverse effects, increased alanine

1

aminotransferase, and increased risk of cough and dyspnea (p < 0.05). In NMA, gilteritinib showed the highest probability for improved prognosis.

Conclusions: FLT3i safely improved prognosis in induction/reinduction stage of *FLT3*(+) AML and further boosted survival benefits from allo-HSCT as maintenance therapy, suggesting better prognosis if FLT3i is combined before and after allo-HSCT. In NMA, gilteritinib potentially achieved the best prognosis, which should be identified in direct trials.

Keywords: acute myeloid leukemia, FLT3 inhibitor, response, survival, toxicity, meta-analysis, network meta-analysis

INTRODUCTION

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by a maturation block and accumulation of myeloid progenitor cells (1). Among the most prevalent AML genetic aberrations, FMS-like tyrosine kinase 3 (FLT3) mutations are detected in approximately one-third of patients (2), comprising about three-quarters of FLT3(+) patients with internal tandem duplication (FLT3-ITD) ranging from 3 to more than 100 amino acids located in the juxtamembrane region and a FLT3 point mutation in the tyrosine kinase domain (TKD) in approximately 8% of newly diagnosed AML (3). FLT3-related mutations induce constitutive activation of FLT3 receptor and trigger the downstream pathways resulting in leukemic cell proliferation, impaired differentiation, and resistance to apoptosis (4). FLT3-ITD(+)patients always manifest poor prognosis, distinguished by high resistance frequency to induction chemotherapy and relapse, decreased response to salvage therapy, and shorter survival. However, TKD influence on prognosis remains contradictory (2).

FLT3 inhibitors (FLT3i) are a type of tyrosine kinase inhibitors with FLT3 inhibitory activity that may be particularly utilized to treat *FLT3*(+) AML with likely improved prognosis. According to current clinical studies, they proved that AML patients benefited from FLT3i (3, 5–7). The following FLT3i are the most frequently estimated in phase 2 or 3 of randomized controlled trials (RCT) and retrospective studies: sorafenib, lestaurtinib, midostaurin, quizartinib and gilteritinib. Typically, sorafenib, lestaurtinib and midostaurin demonstrate activity against multi-kinase. In particular, sorafenib is the most common FLT3i for AML, with high activity against ITD mutations instead of wild-type FLT3 and TKD mutations (8). Lestaurtinib is an indolocarbazole inhibitor, with equal inhibiting impact on FLT3-ITD and -TKD mutations (9, 10). Midostaurin is also a multi-targeted indolocarbazole, with equal activity against mutated FLT3-ITD and -TKD (3). Quizartinib is a FLT3i with potent activity against mutated FLT3-ITD and wild-type FLT3, but without intrinsic activity against TKD mutations (5, 9). Quizartinib can also moderately inhibit KIT (5). Gilteritinib is a highly selective inhibitor of FLT3 and AXL receptor tyrosine kinases, with anti-leukemic activity against ITD and TKD mutations (6, 9) but with weak activity against KIT (6).

These FLT3i are used in various stages, including induction with/without consolidation therapy in newly diagnosed AML, maintenance treatment after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and salvage therapy in refractory and relapsed AML (rrAML). Up to now, no extensive study has been found to comprehensively explore the role of FLT3i in various AML treatment stages and explore which FLT3i probably works the best. Herein, we conducted a meta-analysis in an attempt to clarify the clinical benefit and safety of FLT3i. Data from allo-HSCT in *FLT3*(+) patients were also summarized to observe the effects of FLT3i as the maintenance therapy after allo-HSCT. We further performed network meta-analyses (NMA) and ranked the prognostic effects of various FLT3i based on phase 2 and 3 RCT to check the most effective FLT3i.

METHODS

This study was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (**Supplementary Table 1**) (11) and was registered at PROSPERO (CRD42020158077).

Search Strategy and Study Selection

A literature search was conducted through databases of PubMed, Embase, Cochrane library, China National Knowledge Infrastructure, and Wanfang since inception until September 30th, 2020, following keywords "FMS-like tyrosine kinase 3", "FLT3", "acute myeloid leukemia", "AML", "hematopoietic stem cell transplant", "HSCT", "sorafenib", "lestaurtinib", "midostaurin", "quizartinib", and "gilteritinib". The included reports were: (i) published in English or Chinese, (ii) limited to retrospective cohort studies or RCT reporting the therapeutic effects of FLT3i on AML, especially for FLT3(+) patients, or restricted to studies demonstrating prognostic effects of allo-HSCT on FLT3(+) AML, (iii) designed to contain two arms or more for comparing prognostic influence of FLT3i or allo-HSCT with controls. Studies were excluded if they: (i) reported unavailable or insufficient data, (ii) were reviews, case reports, editorials and letters, (iii) had overlapping cohorts and (iv) were sing-arm studies.

Study selection was conducted in two stages. Initially, abstracts and titles of potential literature were independently browsed and screened by QX and SH according to inclusion and exclusion criteria. Both reviewers then evaluated the candidate articles and decided on their inclusion. Any discrepancy was discussed and, if required, settled through discussion or consultation with a third reviewer (LY). After selecting the

candidate studies, full texts were checked to identify final eligible ones.

Quality Assessment and Publication Bias Investigation

The methodologic quality of primary studies was assessed separately by two reviewers (QX and SH), based on Newcastle-Ottawa-Scale (NOS) (12) and Cochrane Risk of Bias Tool (13) used for quality assessment of retrospective cohort studies and prospective RCT, respectively. Any disparity can be resolved through discussion panel. Publication bias was investigated with funnel plots as well as Begg's (14) and Egger's (15) tests. A *P*-value < 0.05 implied publication bias existence.

Data Collection

Clinical information from the included studies was extracted independently by two authors (QX and SH), and any reported disagreement was settled by discussion or consultation with the third author (LY). The extracted data were comprised of the first author, study characteristics, patients' baseline and prognostic information. The endpoints included overall survival (OS), eventfree survival (EFS), relapse-free survival (RFS), cumulative incidence of relapse (CIR), early death (defined as induction death or 30-day mortality), adverse events and complete remission (CR), defined by revised International Working Group Criteria (16), without requirement of peripheral count recovery for CR. Hazard ratio (HR) was utilized to assess survival, and relative risk (RR) was utilized to evaluate CR, early death and adverse events. Data were preferentially extracted from multivariate analyses. However, in researches without multivariate data, RR and HR were exacted from univariate analyses or calculated from Kaplan-Meier survival curves or numeric reports under the methods provided by Tierney et al. (17).

Statistical Analysis

The pooled HR and 95% confidence intervals (95% CI) for survival were calculated with the inverse variance method, and pooled RR and 95% CI for CR, early death and adverse events were produced from the Mantel-Haenszel method (18). Analyses were conducted with Stata 15.1 using random-effect models to account for heterogeneity between studies. Pooled RR or HR < 1.00 indicated better effects supporting FLT3i or allo-HSCT. It was also considered statistically significant with 95% CI range that did not cover 1.00 and a *p*-value of < 0.05. The χ 2-based Q statistic was used to assess the heterogeneity among studies. Low, moderate, substantial and considerable heterogeneity showed $I^2 < 30\%$, 30%–50%, 50%–75% and > 75%, respectively. A *P*-value \ge 0.10 implied no heterogeneity or slight heterogeneity, whereas P < 0.10 meant significant heterogeneity existence (19). When P-value of heterogeneity was < 0.10, sensitivity and subgroup analyses were conducted to determine significant heterogeneity source.

Bayesian NMA was done with R 4.0.2 by means of a random model *via* packages of "gemtc" and "rjags" in RCT. We also calculated HR or risk ratios (RR) regarding non-FLT3i group as the baseline to act as the effect measure, displayed in forest plots, where RR and HR with 95% credible intervals (95% Crl) were utilized to explain the extent of effects in CR and survival,

respectively. The range of 95% Crl without covering 1.00 implied statistical significance. To estimate relative HR and RR, a Markov Chain Monte Carlo simulation was finished with 10000 adaptations and 100000 iterations of each of the three automatically generated Markov chains. After finishing all simulations, NMA determined the probability that each treatment would be best by calculating the probability of simulations in which a certain treatment ranked best. For each iteration, therapies were ranked according to the evaluated log HR or log RR. The data from Bayesian NMA were compared with data from pairwise meta-analyses to assess inconsistency using the node splitting method (20). Significant inconsistency was indicated if node-splitting analysis showed a *P*-value < 0.05. If no closed-loop was present in the network evidence plot, inconsistency analysis could not be executed. Besides, the network evidence plots were drawn from Stata 15.1.

All analyses were based on published data; therefore, no ethical approval and patient consent were required.

RESULTS

Characteristics of Included Studies

The study selection was shown in **Figure 1**. A total of 38 articles, including 39 studies, were eventually included. The 4th study covered the 5th cohort but focused on different disease statuses, while the 35th and 36th studies contained the same population but involved different treatments. The study characteristics and qualification assessment were listed in **Supplementary Table 2**.

Totally, 6859 AML patients were included, and their studies were conducted in FLT3(+) AML, except for Roellig et al. (7) and Serve et al. (21) (Supplementary Table 2), covering 464 newly diagnosed AML receiving sorafenib plus chemotherapy as induction and consolidation regimen, regardless of FLT3 mutational status. Three studies comprised 380 newly diagnosed FLT3(+) AML patients given sorafenib-related therapies as induction strategy, with or without consolidation and maintenance therapy following allo-HSCT. Six studies (n = 951) only focused on the maintenance therapy of sorafenib after allo-HSCT, and two studies (n = 235) regarded sorafenib as part of salvage therapy following relapse. Midostaurin was used in the stages of induction, consolidation and maintenance treatment in CR in four studies (n = 1604) and one article (n = 60) reported results of midostaurin-related maintenance therapy after allo-HSCT. For lestaurtinib studies, two (n = 500) focused on the induction stage in untreated *FLT3*(+) AML and one (n = 224)involved salvage therapy in FLT3(+) rrAML. In addition, the clinical efficacy of gilteritinib (n = 371) and quizartinib (n = 367)was evaluated in RCT for rrAML, and two studies (n = 178) combined several FLT3i. Finally, fourteen studies (n = 1797) compared prognostic discordance between allo-HSCT and non-HSCT in FLT3(+) AML.

Twenty-eight retrospective cohort studies and eleven RCT were included. The reported eleven RCT comprised four for sorafenib, two for midostaurin, one for gilteritinib, one for quizartinib, and three for lestaurtinib. **Supplementary Figures 1**, **2** showed risk of bias in RCT quality assessment. For survival endpoints, we thought that bias was unlikely because relapse and death were the endpoints



without susceptibility to patient, physician, or outcome assessor bias. The details for NOS score of retrospective studies were listed in **Supplementary Table 3**.

Survival Benefits of FLT3i on Newly Diagnosed AML During Induction Treatment

Twelve studies reported survival across various FLT3i in the induction stage. The summary HR consistently showcased prolonged OS (HR 0.76, 95% CI 0.67–0.87, p < 0.01; heterogeneity: $I^2 = 0.0\%$, P = 0.460) in FLT3i groups but inconsistently in prolonged EFS (HR 0.74, 95% CI 0.56–0.99, p = 0.04; heterogeneity: $I^2 = 90.5\%$, P = 0.000) and better RFS (HR 0.64, 95% CI 0.50–0.82, p < 0.01; heterogeneity: $I^2 = 58.4\%$, P = 0.025) (**Figure 2A** and **Supplementary Table 4**). After excluding the studies of Serve et al. (EFS) (21) and Xuan et al. (RFS) (22), the combined HR became consistent in the sensitivity analyses, indicating longer EFS (HR 0.67, 95% CI 0.58–0.78, p < 0.01; heterogeneity: $I^2 = 43.1\%$, P = 0.153) and better RFS (HR 0.72, 95% CI 0.60–0.85, p < 0.01; heterogeneity: $I^2 = 14.3\%$, P = 0.323) (**Supplementary Figure 3** and **Supplementary Table 4**).

The subgroup analyses were further evaluated among various FLT3i (**Figure 2B** and **Supplementary Table 5**). Sorafenib consistently achieved better OS (HR 0.68, 95% CI 0.51–0.91, p = 0.01; heterogeneity: $I^2 = 13.3\%$, P = 0.330) and RFS (HR 0.49, 95% CI 0.34–0.69, p < 0.01; heterogeneity: $I^2 = 41.3\%$, P = 0.164). Besides, midostaurin consistently prolonged OS (HR 0.74, 95% CI 0.62–0.88, p < 0.01; heterogeneity: $I^2 = 0.0\%$, P = 0.428) but lestaurtinib did not provide better survival (p > 0.05).

Survival Benefits of Allo-HSCT and FLT3i After Allo-HSCT on *FLT3*(+) AML

The survival effects of allo-HSCT in *FLT3*(+) AML were then investigated in 14 studies (**Figure 3A** and **Supplementary Table 4**). EFS and CIR were remarkably consistently prolonged by allo-HSCT (EFS, HR 0.50, 95% CI 0.33–0.77, p < 0.01; heterogeneity: $I^2 = 0.0\%$, P = 0.974; CIR, HR 0.26, 95% CI 0.18–0.38, p < 0.01; heterogeneity: $I^2 = 0.0\%$, P = 0.788). OS and RFS were improved by allo-HSCT but with high heterogeneity (OS, HR 0.52, 95% CI 0.39–0.68, p < 0.01; heterogeneity: $I^2 = 76.9\%$, P = 0.000; RFS, HR 0.49, 95% CI 0.37–0.65, p < 0.01; heterogeneity: $I^2 = 59.2\%$, P = 0.012). After sensitivity analyses,







FIGURE 3 | Survival influences of allo-HSCT and FLT3i as the maintenance therapy after allo-HSCT on FLT3(+) AML. (A) Pooled HR and 95% Cl of allo-HSCT in FLT3 (+) AML for OS, EFS, RFS and CIR; (B) Pooled HR and 95% Cl of all FLT3i as the maintenance therapy after allo-HSCT in FLT3 (+) AML for OS, RFS and CIR; (C) Pooled HR and 95% Cl of each FLT3i as the maintenance therapy after allo-HSCT in FLT3 (+) AML for OS, RFS and CIR. FLT3, FMS-like tyrosine kinase 3; FLT3i, FLT3 inhibitor; Allo-HSCT, allogeneic hematopoietic stem cell transplant; AML, acute myeloid leukemia; OS, overall survival; EFS, event-free survival; RFS, relapse-free survival; CIR, cumulative incidence of relapse; HR, hazard ratio; 95% Cl, 95% confidence interval.

combined HR of OS and RFS became consistent, demonstrating pooled HR of 0.53 for OS (95% CI 0.45–0.64, p < 0.01; heterogeneity: $I^2 = 35.5\%$, P = 0.115) and pooled HR of 0.57 for RFS (95% CI 0.45–0.71, p < 0.01; heterogeneity: $I^2 = 38.5\%$, P = 0.135), respectively (**Supplementary Figure 4**).

We next analyzed FLT3i role as the maintenance treatment after allo-HSCT in eight studies, consistently showing better survival (OS, HR 0.45, 95% CI 0.34–0.60, p < 0.01; heterogeneity: $I^2 = 0.0\%$, P = 0.648; RFS, HR 0.34, 95% CI 0.24–0.47, p < 0.01; heterogeneity: $I^2 = 0.0\%$, P = 0.994; CIR, HR 0.32, 95% CI 0.21–0.46, p < 0.01; heterogeneity: $I^2 = 0.0\%$, P = 0.875; **Figure 3B** and **Supplementary Table 4**). In subgroup analyses (**Figure 3C** and **Supplementary Table 5**), sorafenib consistently exhibited longer survival (OS, HR 0.44, 95% CI 0.33–0.59, p < 0.01; heterogeneity: $I^2 = 0.0\%$, P = 0.557; RFS, HR 0.34, 95% CI 0.24–0.47, p < 0.01; heterogeneity: $I^2 = 0.0\%$, P = 0.994; CIR, HR 0.31, 95% CI 0.20–0.46, p < 0.01; heterogeneity: $I^2 = 0.0\%$, P = 0.994; CIR, HR 0.31, 95% CI 0.20–0.46, p < 0.01; heterogeneity: $I^2 = 0.0\%$, P = 0.827).

Survival Benefits of FLT3i on *FLT3*(+) rrAML During Salvage Therapy

Prognostic effects of FLT3i in salvage regimen in rrAML were estimated among seven studies. After excluding Levis et al. (23) to decrease heterogeneity, the combined HR of OS was changed from 0.65 (95% CI 0.50–0.83, p < 0.01; heterogeneity: $I^2 = 62.7\%$, P =0.013; **Figure 4A**) to 0.60 (95% CI 0.49–0.74, *p* < 0.01; heterogeneity: $I^2 = 29.6\%, P = 0.213$; Supplementary Figure 5) (Supplementary Table 4). RFS was consistently enhanced in FLT3i (HR 0.40, 95% CI 0.21–0.75, p = 0.01; heterogeneity: $I^2 = 0.0\%$, P = 0.544; Figure 4A and Supplementary Table 4). In subgroup analyses (Figure 4B and Supplementary Table 5), pooled HR of OS in sorafenib was 0.48 $(95\% \text{ CI } 0.32-0.71, p < 0.01; \text{ heterogeneity: } I^2 = 0.0\%, P = 0.662), \text{ and}$ only one study was involved in gilteritinib, quizartinib, and lestaurtinib, respectively. Better OS was observed in gilteritinib (HR 0.64, 95% CI 0.49–0.83, *p* < 0.01) and quizartinib (HR 0.76, 95% CI 0.58–0.98, p = 0.04). However, lestaurtinib did not support better survival (p > 0.05).

Response of FLT3i in AML

CR from 15 studies was assessed (Figure 5A and Supplementary Table 4), and better CR was heterogeneously realized in FLT3i group in both newly diagnosed AML (RR 0.88, 95% CI 0.78-0.99, p = 0.04; heterogeneity: $I^2 = 63.9\%$, P = 0.005) and rrAML (RR 0.66, 95% CI 0.48–0.90, p = 0.01; heterogeneity: $I^2 = 54.4\%$, P = 0.052). After sensitive analysis, combined RR of CR in rrAML became consistent, demonstrating pooled RR of 0.61 (95% CI 0.46–0.81, p < 0.01; heterogeneity: $I^2 = 44.3\%$, P = 0.126). In the subgroup analyses for newly diagnosed AML (Figure 5B and Supplementary Table 5), pooled RR of sorafenib, midostaurin, and lestaurtinib was 0.88 (95% CI 0.68–1.12, p = 0.32; heterogeneity: $I^2 = 83.1\%$, P =0.001), 0.85 (95% CI 0.71–1.02, p = 0.08; heterogeneity: $I^2 = 34.2\%$, P = 0.218) and 1.36 (95% CI 0.67–2.76, p = 0.40; heterogeneity: $I^2 =$ 0.0%, P = 0.652), respectively. In the subgroup analyses for salvage regimen in rrAML (Figure 5B and Supplementary Table 5), HR for sorafenib, lestaurtinib, gilteritinib, and quizartinib was 0.45 (95% CI 0.25-0.81, p = 0.01), 0.79 (95% CI 0.49-1.28, p = 0.34),0.45 (95% CI 0.29-0.71, *p* < 0.01), and 0.56 (95% CI 0.41-0.77, *p* < 0.01), respectively.

Effectiveness of FLT3i to the *FLT3-ITD* Allelic Ratio

The treatment effectiveness of FLT3i was then analyzed in patients with low and high FLT3-ITD allelic ratio, respectively. Due to the lack of relevant information involved in response, survival benefits of FLT3i were summarized in Figure 6. Exact stratifications of FLT3-ITD ratio in different studies were summarized in Supplementary Table 6. For OS, FLT3i consistently illustrated improved survival in both of high (HR 0.86, 95% CI 0.79–0.94, p <0.01; heterogeneity: $I^2 = 0.0\%$, P = 0.654) and low ratio (HR 0.83, 95% CI 0.69–0.99, p = 0.04; heterogeneity: $I^2 = 0.0\%$, P = 0.807) when compared to non-FLT3i group. However, FLT3i significantly prolonged RFS in patients with high-ratio FLT3-ITD (HR 0.92, 95% CI 0.85–0.99, p = 0.03; heterogeneity: $I^2 = 0.0\%$, P = 0.368) rather than those with low-ratio FLT3-ITD mutations (HR 0.97, 95% CI 0.93–0.1.01, p = 0.15; heterogeneity: $I^2 = 0.0\%$, P = 0.483), when compared to non-FLT3i arm. Finally, there was only one study involved in EFS, showing no prolonged survival in FLT3i group in both of high and low FLT3-ITD ratio.

Harm

Totally, early death and 21 types of toxic effects were analyzed (**Supplementary Table 7**) in sorafenib, gilteritinib, quizartinib, midostaurin, and lestaurtinib. FLT3i consistently showed significantly increased risk of thrombocytopenia (FLT3i *vs.* non-FLT3i: 28.96% *vs.* 18.36%; RR, 2.20; 95% CI, 1.39–3.48, p = 0.0008; $I^2 = 55.2\%$, P = 0.108), neutropenia (FLT3i *vs.* non-FLT3i: 34.92% *vs.* 22.30%; RR, 1.32; 95% CI, 1.05–1.65, p = 0.016; $I^2 = 0.0\%$, P = 0.620), as well as anemia (FLT3i *vs.* non-FLT3i: 41.89% *vs.* 33.50%; RR, 1.26; 95% CI, 1.01–1.57, p = 0.04; $I^2 = 0.0\%$, P = 0.460) regardless of grades.

Besides, FLT3i were clearly related to higher risk of skin-related adverse effects at all grades (FLT3i vs. non-FLT3i: 27.42% vs. 22.62%; RR, 1.37; 95% CI, 1.01–1.87, p = 0.045; $I^2 = 49.9$ %, P =0.092), especially for grades \geq 3 (FLT3i *vs.* non-FLT3i: 7.46% *vs.* 4.43%; RR, 2.07; 95% CI, 1.44-2.99, p = 0.0001) with low heterogeneity ($I^2 = 0.0\%$, P = 0.543). FLT3i also consistently showed a tendency of increased risk for all-grade gastrointestinalrelated toxicities (FLT3i vs. non-FLT3i: 38.80% vs. 26.28%; RR, 1.49; 95% CI, 1.00–2.23, p = 0.051; $I^2 = 15.10\%$, P = 0.278). Additionally, significantly increased alanine aminotransferase was found in FLT3i group at all grades (FLT3i vs. non-FLT3i: 27.72% vs. 6.90%; RR, 4.13; 95% CI, 2.45–6.95, p = 0.000; $I^2 = 0.0\%$, P =0.528) and grade ≥ 3 (FLT3i vs. non-FLT3i: 10.45% vs. 7.90%; RR, 1.68; 95% CI, 1.04–2.72, p = 0.034; $I^2 = 14.80\%$, P = 0.309). Cardiacrelated adverse events were mainly reported in sorafenib in all grades (sorafenib vs. control: 23.08% vs. 15.74%; RR, 1.47; 95% CI, 1.01-2.14, p = 0.044; $I^2 = 0.0\%$, P = 0.336) and grade ≥ 3 (sorafenib *vs*. control: 4.76% *vs*. 2.12%; RR, 2.68; 95% CI, 1.09–6.59, *p* = 0.032; $I^2 = 0.0\%$, P = 0.407). Higher risk of all-grade cough (FLT3i vs. non-FLT3i: 26.28% vs. 11.82%; RR, 2.18; 95% CI, 1.28–3.73, p = 0.004; $I^2 = 42.4\%$, P = 0.188) and dyspnea (FLT3i vs. non-FLT3i: 21.97% vs. 7.39%; RR, 2.92; 95% CI, 1.75–4.90, *p* = 0.000; *I*² = 0.0%, *P* = 0.415) was reported in FLT3i group.

Finally, there was no clear relationship between FLT3i as well as high risk of early death and acute/chronic graft-versus-host disease (GVHD).

Study	Year	ELT3i	Control			HR (95% CI)	Weight
, and the second s	rear	12101					5570 Cl)	treight
OS				_				
Kuan	2019	53	30	•	-	0.53 (0.29, 0.96)	6.54
Bazarbachi(2)	2019	34	118	• ;		0.44 (0.26, 0.75)	7.63
Perl	2019	247	124	+		0.64 (0.49, 0.83)	13.93
Cortes	2019	245	122		•	0.76 (0.58, 0.98)	14.02
Papayannidis	2018	34	15	 •		0.20 (0.05, 0.75)	1.84
Takahashi (1)	2013	45	75	•	<u> </u>	0.58 (0.38, 0.88)	9.83
Levis	2011	112	112		•	1.04 (0.78, 1.39)	13.21
Subtotal (I–sqi	uared =	62.7%, p) = 0.013)	4	>	0.65 (0.50, 0.83)	67.00
EFS								
Perl	2019	247	124	+	•	0.79 (0.58, 1.09)	12.41
Cortes	2019	245	122	1	•	0.90 (0.70, 1.16)	14.22
Subtotal (I-squ	uared =	0.0%, p	= 0.549)	i i i	<u>क</u>	0.86 (0.70, 1.04)	26.63
ĸ⊢s Kuan	2019	53	30	-	_	0.42 /	0.22, 0.82)	5.68
Perl	2019	52	13			0.72 (0.02.1.89)	0.69
Subtotal (I-sou	Jared =	0.0% n	= 0.544)	\sim		0.40 (0.21. 0.75)	6.37
		2.070, p		\sim		0.40 (,,	0.57
Overall (I-squa	ared = 5	6.6%, p	= 0.011)	\$	>	0.68 (0.56, 0.82)	100.00
NOTE: Weights	are fro	m rando	m effects analysis	1				
Study	Vear	ELT3i	Control				35% CI)	% Weight
Study	Year	FLT3i	Control	 		 HR (S	95% CI)	% Weight
Study OS for Sorafe Xuan	Year ni b 2019	FLT3i	Contro I	 	_	 HR (9	95% CI) 	% Weight 6.54
Study OS for Sorafer Xuan Bazarbachi(2 Subtotal (1–so	Year ni b 2019) 2019 quared :	FLT3i 53 34 = 0.0%, p	Contro I 30 118 = 0.662)	 ↓ +	-	 HR (9 0.53 (0 0.44 (0 0.48 (0	95% CI) 0.29, 0.96) 0.26, 0.75) 0.32, 0.71)	% Weight 6.54 7.63 14.17
Study OS for Sorafer Xuan Bazarbachi(2 Subtotal (1–sr RFS for Sorafe	Year ni b 2019) 2019 quared :	FLT3i 53 34 = 0.0%, p	Contro I 30 118 = 0.662)	 ** ()		HR (5 0.53 (0 0.44 (0 0.48 (0	95% CI) 0.29, 0.96) 0.26, 0.75) 0.32, 0.71)	% Weight 6.54 7.63 14.17
Study OS for Sorafer Xuan Bazarbachi(2 Bazarbachi(2 RFS for Sorafe Xuan	Year ni b 2019) 2019 quared : 2019 2019	FLT3i 53 34 = 0.0%, p	Control 30 118 >= 0.662) 30			 HR (5 0.53 (0 0.44 (0 0.48 (0 0.42 (0	25% Cl) 0.29, 0.96) 0.26, 0.75) 0.32, 0.71)	% Weight 6.54 7.63 14.17 5.68
Study OS for Sorafet Xuan Bazarbachi(2 Subtotal (I–so Kuan Subtotal (I–so	Year ni b 2019) 2019 quared : 2019 quared :	FLT3i 53 34 = 0.0%, p 53 = .%, p =	Contro I 30 118 = 0.662) 30 .)		-	 HR (5 0.53 (0 0.44 (0 0.48 (0 0.42 (0 0.42 (0	95% Cl) 0.29, 0.96) 0.26, 0.75) 0.32, 0.71) 0.22, 0.82) 0.22, 0.82)	% Weight 6.54 7.63 14.17 5.68 5.68
Study OS for Sorafet Xuan Bazarbachi(2 Subtotal (I–so RFS for Sorafe Xuan Subtotal (I–so OS for Gilterit	Year ni b 2019) 2019 quared : 2019 quared : quared :	FLT3i 53 34 = 0.0%, p 53 = .%, p =	Control 30 118 = 0.662) 30 .)			 HR (5 0.53 (0 0.44 (1 0.48 (1 0.42 (1 0.42 (1	0.29, 0.96) 0.26, 0.75) 0.32, 0.71) 0.22, 0.82) 0.22, 0.82)	% Weight 6.54 7.63 14.17 5.68 5.68
Study OS for Sorafer Xuan Bazarbachi(2 Subtotal (I–so RFS for Sorafe Xuan Subtotal (I–so OS for Gilterit Perl Subtotal (I–so	Year ni b 2019 Quared a 2019 Quared a ini b 2019 2019	FLT3i 53 34 = 0.0%, p 53 = .%, p = 247	Control 30 118 = 0.662) 30 .) 124	ו _ ◊+ +		 HR (5 0.53 (0 0.44 (0 0.48 (0 0.42 (0 0.42 (0 0.64 (0 0.64 (0	0.29, 0.96) 0.26, 0.75) 0.32, 0.71) 0.22, 0.82) 0.22, 0.82) 0.49, 0.83)	% Weight 6.54 7.63 14.17 5.68 5.68 5.68 13.93 13.93
Study OS for Sorafet Xuan Bazarbachi(2 Subtotal (I–st RFS for Sorafe Xuan Subtotal (I–st OS for Gilterit Perl Subtotal (I–st	Year ni b 2019) 2019 quared : 2019 quared : 2019 quared :	FLT3i 53 34 = 0.0%, p 53 = .%, p = 247 = .%, p =	Control 30 118 >= 0.662) , 30 , 124	0+ -\\+ \\+		HR (0.53 (0.44 (0.48 (0.42 (0.42 (0.42 (0.64 (0.64 (05% Cl) 0.29, 0.96) 0.26, 0.75) 0.32, 0.71) 0.22, 0.82) 0.22, 0.82) 0.49, 0.83) 0.49, 0.83)	% Weight 6.54 7.63 14.17 5.68 5.68 13.93 13.93
Study OS for Sorafet Xuan Bazarbachi(2 Subtotal (I-so RFS for Sorafe Xuan Subtotal (I-so OS for Gitterit Perl Subtotal (I-so EFS for Gitterit Perl Det	Year ni b 2019) 2019 quared = 2019 quared = inib 2019 quared = inib	FLT3i 53 34 = 0.0%, p 53 = .%, p = 247 = .%, p =	Control 30 118 0 = 0.662) .) .) 124 124	 \uparrow		HR (5 0.53 (0.44 (0.44 (0.42 (0.42 (0.42 (0.42 (0.64 (0.6	055% CI) 0.29, 0.96) 0.26, 0.75) 0.32, 0.71) 0.22, 0.82) 0.22, 0.82) 0.49, 0.83) 0.49, 0.83)	% Weight 7.63 14.17 5.68 5.68 13.93 13.93
Study OS for Sorafe Xuan Bazarbachi(2 Subotal (I–so Xuan Subtotal (I–so Subtotal (I–so Subtotal (I–so ES for Gilterit Perl Subtotal (I–so	Year ni b 2019 2019 2019 2019 2019 2019 2019 2019 2019 2019 2019 2019	FLT3i 53 34 = 0.0%, p 53 = .%, p = 247 = .%, p =	Control 30 118 20 = 0.662) .) 124 .) 124	$\rightarrow \rightarrow $	•	HR (9 0.53 (0.44 (0.42 (0.42 (0.42 (0.42 (0.42 (0.42 (0.44 (0.64 (0.79 (0.79 (55% C() 1.29, 0.96) 1.26, 0.75) 1.32, 0.71) 1.22, 0.82) 1.22, 0.82) 1.49, 0.83) 1.49, 0.83) 1.49, 0.83) 1.49, 0.83) 1.49, 0.83) 1.49, 0.83)	% Weight 7.63 14.17 5.68 5.68 13.93 13.93 13.93 12.41
Study OS for Sorafe Xuan Bazarbachi(2 Subtotal (I–so Subtotal (I–so Subtotal (I–so ErS for Gilterit Perl Subtotal (I–so	Year nib 2019) 2019 quared : 2019 quared : 2019 quared : 2019 quared : 2019 quared :	FLT3i 53 34 = 0.0%, p 53 = .%, p = 247 = .%, p =	Control 30 118 = 0.662) , 30 , 124 , 124	 \rightarrow \uparrow \downarrow		HR (5 0.53 (0 0.44 (0 0.42 (0 0.42 (0 0.64 (0 0.64 (0 0.79 (0 0.79 (0	55% (1) 1.29, 0.96) 1.26, 0.75) 1.32, 0.71) 1.22, 0.82) 1.22, 0.82) 1.22, 0.82) 1.24, 0.83) 1.49, 0.83) 1.58, 1.09) 1.58, 1.09)	% Weight 6.54 7.63 14.17 5.68 5.68 13.93 13.93 13.93 12.41 12.41
Study OS for Sorafe Xuan Bazarbachi(2 Subtoral (1–so Subtoral (1–so OS for Gilterit Perl Subtoral (1–so EFS for Gilteri Perl Subtoral (1–so RFS for Gilteri Perl Perl	Year nib 2019) 2019 quared : 2019 quared : 2019 quared : tinib 2019 quared : tinib 2019 quared : 2019	FLT3i 53 34 53 53 53 53 53 247 247 247 247 247 247 52	Control 30 118 > 0.662) .) 30 .) 124 .) 124 .) 13	\sim \wedge \wedge	*	HR (5 0.53 (i 0.44 (i 0.42 (i 0.42 (i 0.42 (i 0.64 (i 0.64 (i 0.79 (i 0.79 (i 0.79 (i	95% CI) 2.29, 0.96) 1.26, 0.75) 3.32, 0.71) 3.22, 0.82) 3.22, 0.82) 3.22, 0.82) 3.22, 0.83) 3.24, 0.83) 3.49, 0.83) 3.58, 1.09) 3.58, 1.09) 3.58, 1.09) 3.58, 1.09)	% Weight 6.54 7.63 14.17 5.68 5.68 13.93 13.93 13.93 12.41 12.41 12.41 0.69
Study OS for Sorafei Xuan Bazarbachi(2 Subtotal (1–ss Xuan Subtotal (1–ss Subtotal (1–ss Subtotal (1–ss ErS for Gilterit Perl Subtotal (1–ss FS for Gilterit Perl Subtotal (1–ss RES for Gilterit Perl Subtotal (1–ss	Year ni b 2019) 2019 quared : 2019 2019 quared : 2019 quared : 2019 quared : 2019 quared : 2019 quared :	FLT3i 53 34 0.0%, p = .%, p = .%, p = .%, p = .%, p = .%, p	Control 30 118 >= 0.662) .) 30 .) 124 .) 124 .) 124 .)			HR (5 0.53 (0 0.44 (0 0.42 (0 0.42 (0 0.42 (0 0.64 (0 0.64 (0 0.79 (0 0.79 (0 0.79 (1 0.72 (1	25% CI) .229, 0.96) .226, 0.75) .322, 0.75) .322, 0.82) .222, 0.82) .229, 0.83) .249, 0.83) .249, 0.83) .258, 1.09) .258, 1.09) .258, 1.09) .258, 1.09) .258, 1.09) .259, 0.96 .259, 0.	% Weight 6.54 7.63 14.17 5.68 5.68 13.93 13.93 12.41 12.41 12.41 0.69 0.69
Study OS for Sorafe Xuan Bazarbachi(2 Subtotal (I-ss Xuan Subtotal (I-ss Subtotal (I-ss Subtotal (I-ss EFS for Gilterit Peri Subtotal (I-ss FS for Gilterit Peri Subtotal (I-ss FS for Gilterit Peri Subtotal (I-ss Subtotal (I-ss OS for Gilterit Peri Subtotal (I-ss OS for Oilterit Peri	Year ni b 2019	FLT3i 53 34 = 0.0%, p = .%, p = 247 = .%, p = 52 = .%, p =	Control 30 118 p = 0.662) .) 30 .) 124 .) 124 .) 13			HR (5 0.53 (0 0.44 (0 0.42 (0 0.42 (0 0.64 (0 0.64 (0 0.79 (0 0.79 (0 0.21 (0 0.21 (0	0.25, 0.96) 1.26, 0.75) 1.27, 0.82) 1.22, 0.82) 1.22, 0.82) 1.22, 0.82) 1.22, 0.82) 1.49, 0.83) 1.49, 0.83) 1.49, 0.83) 1.49, 0.83) 1.58, 1.09) 1.58,	% Weight 6.54 7.63 14.17 5.68 5.68 13.93 13.93 13.93 12.41 12.41 0.69 0.69
Study OS for Sorafe Xuan Bazarbachi(2 Subtotal (I–sc Subtotal (I–sc Subtotal (I–sc EFS for Gilteri Peri Subtotal (I–sc PFI Subtotal (I–sc PFS for Gilteri Peri Subtotal (I–sc OS for Quizar OS for Quizar OS for Quizar	Year ini b 2019	FLT3i 53 34 = 0.0%, p = .%, p = 247 = .%, p = 247 = .%, p = 52 = .%, p = 245	Control 30 118 p = 0.662) 30 124 124 124 124 124 124 124			HR (5 0.53 (0 0.44 (0 0.48 (0 0.42 (0 0.42 (0 0.64 (0 0.79 (0 0.79 (0 0.79 (1 0.21 (0 0.21 (0 0.76 (1	25% CI) 7.29, 0.96() 2.26, 0.75() 3.32, 0.71() 7.22, 0.82() 7.22, 0.82() 7.22, 0.83() 7.49, 0.83() 7.49, 0.83() 7.58, 1.09() 7.58, 1.09() 7.58, 1.09() 7.58, 1.09() 7.58, 1.09() 7.58, 1.09() 7.58, 1.09() 7.58, 0.98() 7.58, 0.98()	% Weight 6.54 7.63 14.17 5.68 5.68 13.93 13.93 13.93 12.41 12.41 12.41 12.41 12.41 12.41 12.41
Study OS for Sorafe Xuan Bazarbachi(2 Subtotal (I–so - RS for Sorafe Xuan OS for Gilteri Perl Subtotal (I–so - EFS for Gilteri Perl Subtotal (I–so - Subtotal (Year ini b 2019	FLT3i 53 34 0.0%, p = .%, p = 247 2.47 p = .%, p = 247 2.47 p = .%, p = 2.47 2.47 p = .%, p = 2.47 2.47 p = .%, p = 2.47 2.47 p = .%, p = 2.47 2.47 p = .%, p = 2.47 p = .%, p = .%,	Control 30 118 = 0.662) 30 .) 124 .) 124 .) 122			HR (5 0.53 (0 0.44 (0 0.42 (0 0.42 (0 0.42 (0 0.42 (0 0.64 (0 0.79 (0 0.79 (0 0.79 (0 0.79 (0 0.21 (0 0.21 (0 0.21 (0 0.76 (0	25% CI) 2.29, 0.96) 1.26, 0.75) 3.32, 0.75) 3.22, 0.82) 2.22, 0.82) 2.22, 0.82) 3.22, 0.83) 3.24, 0.83) 3.49, 0.83) 3.49, 0.83) 3.58, 1.09) 3.58, 1.09) 3.02, 1.89) 3.02, 1.91) 3.58, 0.98)	% Weight 6.54 7.63 14.17 5.68 5.68 13.93 13.93 13.93 12.41 12.41 12.41 12.41 0.69 0.69 14.02
Study OS for Sorafe Xuan Bazarbachi(2 Subtotal (1–st Xuan Peri Subtotal (1–st OS for Gilterit Peri Subtotal (1–st RFS for Gilteri Peri Subtotal (1–st OS for Gilteri Peri Subtotal (1–st OS for Gilteri Subtotal (1–st EFS for Gilteri Subtotal (1–st EFS for Gilteri Subtotal (1–st EFS for Gilteri Subtotal (1–st EFS for Gilteri Cortes	Year nib 2019 2029 quared : 2019 quared : 2019 quared : 2019 quared : tinib 2019 quared : tinib 2019 quared : 100 2019 quared : 100 2019 100 100 100 100 100 100 100	FLT3i 53 34 e 0.0%, p = .%, p = .%, p = .%, p = .%, p = .%, p = .%, p	Control 30 118 10 10 10 10 10 10 10 10 10 10			HR (5 0.53 (0 0.44 (0 0.48 (0 0.42 (0 0.42 (0 0.42 (0 0.64 (0 0.79 (0 0.79 (0 0.76 (0	25% CI) 2.29, 0.96) 1.26, 0.75) 3.32, 0.71) 2.22, 0.82) 3.22, 0.82) 3.22, 0.82) 3.24, 0.83) 3.49, 0.83) 3.58, 1.09) 3.58, 1.09) 3.58, 0.98) 3.58, 0.98)	% Weight 6.54 7.63 14.17 5.68 5.68 13.93 13.93 13.93 12.41 12.41 12.41 12.41 0.69 0.69 14.02
Study OS for Sorafei Xuan Bazarbachi(2 Subtotal (1–sc Subtotal (1–sc Subtotal (1–sc OS for Gilterit Perl Subtotal (1–sc OS for Gilterit Perl Subtotal (1–sc OS for Gilterit Perl Subtotal (1–sc OS for Gilterit Perl Subtotal (1–sc Subtotal (1–sc Subtotal (1–sc Subtotal (1–sc Subtotal (1–sc Subtotal (1–sc Subtotal (1–sc) Subtotal (1–sc) Subtotal (1–sc) Subtotal (1–sc) Subtotal (1–sc)	Year nib 2019 2019 quared 2019 quared 2019 quared 2019 quared 2019 quared 2019 quared 2019 2019 2019 2019 2019 2019	FLT3i 53 34 0.0%, p = .%, p = .%, p = .%, p = .%, p = .%, p = .%, p = .247 52 = .%, p = .247 52 = .%, p = .245	Control 30 118 p = 0.662) 30 124 124 124 113 122 122			HR (5 0.53 (0 0.44 (0 0.48 (0 0.42 (0 0.79 (0 0.21 (0 0.76 (0 0.76 (0 0.76 (0 0.90 (0	25% CI) 2.29, 0.96) 2.26, 0.75) 3.22, 0.71) 7.22, 0.82) 7.22, 0.8	% Weight 6.54 7.63 14.17 5.68 5.68 13.93 13.93 12.41 12.41 0.69 0.69 0.69 14.02 14.02 14.02
Study OS for Sorafe Xuan RES for Sorafe Xuan OS for Gilterit Peri Subtotal (I–sc EFS for Gilterit Peri Subtotal (I–sc RES for Gilterit Peri Subtotal (I–sc RES for Gilteri Peri Subtotal (I–sc EFS for Guizar Cortes Subtotal (I–sc	Year ni b 2019	FLT3i 53 34 0.0%, p = .%, p = 247 = .%, p = 247 247 = .%, p = 247 = .%, p = 247 = .%, p = 247 = .%, p =	Control 30 118 p = 0.662) 30 124 124 124 13 122 122			HR (5 0.53 (6 0.44 (6 0.48 (6 0.42 (1 0.42 (1 0.42 (1 0.42 (1 0.42 (1 0.42 (1 0.79 (1 0.79 (1 0.79 (1 0.79 (1 0.76 (1 0.76 (1 0.76 (1 0.76 (1 0.76 (1 0.76 (1))))))))))))))))))))))))))))))))))))	255% C[) 2.29, 0.96() 2.26, 0.75() 3.32, 0.71() 2.22, 0.82() 2.22, 0.82() 2.49, 0.83() 2.49, 0.83() 2.49, 0.83() 2.58, 1.09() 2.58, 1.09() 2.58, 1.09() 2.58, 0.98() 2.58, 0.98() 2.59,	% Weight 6.54 7.63 14.17 5.68 5.68 13.93 13.93 13.93 12.41 12.41 12.41 0.69 0.69 14.02 14.02 14.02 14.02
Study OS for Sorafe Xuan FRS for Sorafe Xuan FSS for Sorafe Xuan OS for Gilterit Peri Subtotal (I–sc Subtotal (I–sc))	Year ni b 2019) 2019 quared : 2019 quared : 2019 ;	FLT3i 53 34 53 53 53 53 53 54 7 52 52 52 52 52 52 52 52 52 52 52 52 52	Control 30 118 p = 0.662) 30 p = 0.662) p = 124 p = 124 p = 122 p = 122			HR (5 0.53 (0 0.44 (0 0.42 (0 0.42 (0 0.42 (0 0.42 (0 0.42 (0 0.42 (0 0.42 (0 0.42 (0 0.79 (0 0.79 (0 0.79 (0 0.76 (0 0.76 (0 0.90 (0 0.90 (0	25% C1) 2.29, 0.96() 2.26, 0.75() 3.22, 0.82() 3.22, 0	% Weight 6.54 7.63 14.17 5.68 5.68 13.93 13.93 13.93 12.41 14.02 14.02 14.02 14.12 14.24 14.22 14.22 14.22 14.24 14.22 14.24 14.22 14.24 14.24 14.24 14.24 14.24 14.24 14.25 1
Study OS for Sorafe Xuan Bazarbachi(I-st Subtotal (I-st Xuan Subtotal (I-st Subtotal (I-st Subtotal (I-st Subtotal (I-st Subtotal (I-st Cortes Subtotal (I-st Cortes) Subtotal (I-st Cortes)	Year ni b 2019 quared : 2019 quared : 2019 ; 2019 ; 2019 ; 2019 ; 2019 ; 2019 ; 2019 ; 2019 ; 2019 ; 2019 ; 2019 ; 2019 ; 2019 ; 2019 ; 2019 ; 2019 ; 2019 ; 2019 ; 2019 ;	FLT3i 53 34 53 53 53 53 53 54 52 247 7 247 7 247 9 247 52 247 9 245 9 245 9 12 245 9 12 12 12 12 12 12 12 12 12 12	Control 30 118 p = 0.662) 30 124 124 124 124 122 122 122 122 122 122			HR (5 0.53 (0 0.44 (0 0.42 (0	25% CI) 2.29, 0.96) 1.26, 0.75) 3.22, 0.82) 1.22, 0.82) 1.22, 0.82) 1.22, 0.82) 1.22, 0.82) 1.22, 0.82) 1.22, 0.82) 1.22, 0.82) 1.23, 0.83) 1.24, 0.83) 1.25, 0.98) 1.25, 0.9	% Weight 6.54 7.63 14.17 5.68 5.68 13.93 13.93 13.93 12.41 12.41 12.41 12.41 12.41 14.02 14.02 14.02 14.22 14.22 14.22 13.21
Study OS for Sorafe: Xuan Bazarbachi(2 Subtotal (1–st Subtotal (1–st Subtotal (1–st Subtotal (1–st Subtotal (1–st Subtotal (1–st OS for Gilteri Peri Subtotal (1–st OS for Gilteri Subtotal (1–st OS for Gilteri Cortes Subtotal (1–st Cortes Subtotal (1–st Cortes Subtotal (1–st OS for Cuizar Cortes Subtotal (1–st OS for Cuizar Cortes Subtotal (1–st OS for Lestau Levis Subtotal (1–st OS for Lestau	Year ni b 2019 2019 2019 2019 2019 2019 2019 2019	FLT3i 53 34 0.0%, p = .%, p = .247 = .%, p =	Control 30 118 10.662) 30 .) 30 .) 124 .) 124 .) 124 .) 124 .) 122 .) 122 .) 122 .) 122 .) 122 .) 122 .) 122 .) 122 .) 122 .) 122 .) 122 .) 122 .) 122 .) 122 .) 122 .) 124 .) 125 .) 126 .) 127 .) .) 127 .) .) .) .) .) .) .) .) .) .)			HR (5 0.53 (0 0.44 (0 0.42 (0	25% Cl) 2.29, 0.96) 1.26, 0.75) 3.32, 0.71) 7.22, 0.82) 1.22, 0.82) 1.22, 0.82) 1.22, 0.82) 1.22, 0.82) 1.23, 0.83) 1.49, 0.83) 1.58, 1.09) 1.58, 1.09) 1.58, 0.98) 1.58, 0.98) 1.70, 1.16) 1.70, 1.16) 1.78, 1.39) 1.78, 1.39)	% Weight 6.54 7.63 14.17 5.68 5.68 13.93 13.93 12.41 12.41 12.41 12.41 12.41 12.41 12.41 12.41 14.02 14.02 14.02 14.02 14.22 14.22 13.21
Study OS for Sorafe Xuan RES for Sorafe Xuan OS for Gilterit Peri Subtotal (I–sc EFS for Gilterit Peri Subtotal (I–sc EFS for Gilterit Peri Subtotal (I–sc RES for Gilterit Peri Subtotal (I–sc RES for Gultar Cortes Subtotal (I–sc Subtotal (I–sc Subtotal (I–sc Cortes Subtotal (I–sc Subtotal (I–sc) Subtotal (I–sc)	Year 10 June 2019 20	FLT3i 53 34 = 0.0%, p = 53 = .%, p = 247 = .%, p = 247 = .%, p = 52 = .%, p = 245 = .%, p = 112 = .%, p =	Control 30 118 p = 0.662) , 30 , 124 , 124 , 124 , 124 , 122 , 122 , 112 , 112			HR (5 0.53 (6 0.44 (6 0.44 (6 0.42 (0 0.42 (0	25% C1) 7.29, 0.96() 2.20, 0.75() 3.32, 0.71() 7.22, 0.82() 7.22, 0.82() 7.22, 0.82() 7.22, 0.82() 7.22, 0.82() 7.23, 0.83() 7.24, 0.83() 7.25, 0.98() 7.25, 0.98() 7.70, 1.16() 7.78, 1.39() 7.78, 1	% Weight 6.54 7.63 14.17 5.68 5.68 13.93 13.93 12.41 12.41 12.41 0.69 0.69 14.02 14.02 14.02 14.02 14.22 14.22 13.21
Study OS for Sorafet Xuan Bazarbach(2 Subtotal (I–sc Kuan Perl Subtotal (I–sc EFS for Gilteri Perl Subtotal (I–sc Subtotal (I–sc Cortes Subtotal (I–sc Cor	Year nib 2019 2019 2029 2011 2019 2011 2	FLT3i 53 34 = 0.0%, p = %, p = 247 = .%, p = 247 = .%, p = .%, p	Control 30 118 = 0.662) .) 30 .) 124 .) 124 .) 124 .) 122 .) 122 .) 122 .) 112 .) 112 			HR (5 0.53 (0 0.44 (0 0.42 (0	25% C1) 2.29, 0.96() 2.26, 0.75() 3.22, 0.82() 3.22, 0	% Weight 6.54 7.63 14.17 5.68 5.68 13.93 13.93 13.93 12.41 12.41 12.41 12.41 12.41 12.41 12.41 12.41 12.41 12.41 12.41 12.41 13.21 13.21 13.21 13.21 13.21 13.21
Study OS for Sorafe Xuan Bazarbachi(2 Subtotal (I–sr Subtotal (I–sr Subtotal (I–sr EFS for Gilteri Perl Subtotal (I–sr EFS for Gilteri Perl Subtotal (I–sr Cortes Subtotal (I–sr EFS for Guizar Cortes Subtotal (I–sr Cortes Subtotal (I–sr OS for Cuizar Cortes Subtotal (I–sr OS for Cuizar Cortes Subtotal (I–sr OS for Lestau Levis Subtotal (I–sr	Year nib 2019 2019 2029 2019 2	FLT31 53 34 e 0.0%, p = 53 e .%, p = 247 e .%, p = 247 e .%, p = 247 e .%, p = 245 e .%, p = 245 e .%, p = 112 e .%, p = 34 45 55, 8%, %	Control 30 118 p = 0.662) 30 124 124 124 124 122 122 122 112 122 112 122 112 122 112 122 112 122 122 122 122 122 122 122 122 122 122 122 122 122 125 125			HR (5 0.53 (0 0.44 (0 0.42 (0 0.42 (0 0.42 (0 0.42 (0 0.42 (0 0.42 (0 0.42 (0 0.42 (0 0.42 (0 0.44 (0 0.44 (0 0.76 (0 0.90 (0)	25% CI) 2.29, 0.96) 1.26, 0.75) 3.22, 0.82) 2.22, 0.82) 2.22, 0.82) 2.22, 0.82) 3.22, 0.82) 3.22, 0.82) 3.22, 0.83) 3.24, 0.83) 3.258, 1.09) 3.258, 1.09) 3.258, 1.09) 3.258, 0.98) 3.270, 1.16) 3.78, 1.39) 3.78, 1.39) 3.78, 1.39) 3.78, 1.39) 3.78, 1.39) 3.58, 0.75) 3.80, 0.83	% 6.54 7.63 14.17 5.68 5.68 13.93 12.41 0.69 14.02 14.22 14.22 14.22 13.21 1.84 9.83 11.67
Study OS for Sorafe Xuan Bazarbachi(2 Subtotal (1–st Xuan RFS for Sorafe Xuan OS for Gilterit Peri Subtotal (1–st Subtotal (1–st Subtotal (1–st OS for Gilteri Peri Subtotal (1–st OS for Gilteri Peri Subtotal (1–st OS for Quizar Cortes Subtotal (1–st OS for Quizar Cortes Subtotal (1–st OS for Quizar Cortes Subtotal (1–st OS for Lateria) Subtotal (1–st OS for FLT3) Papayannidi (1–st Takahashi (1) Subtotal (1–st	Year ni b 2019 2018	FLT3i 53 34 = 0.0%, p = .%, p	Control 30 118 p = 0.662) 30 .) 30 .) 124 .) 124 .) 124 .) 124 .) 122 .) .) 122 .) .) 124 .) .) .) .) .) .) .) .) .) .)			HR (5 0.53 (0 0.44 (0 0.44 (0 0.42 (0	25% Cl) 229, 0.96) 1,26, 0.75) 3,32, 0.71) 2,22, 0.82) 2,22, 0.82) 2,22, 0.82) 2,22, 0.82) 2,22, 0.82) 2,22, 0.82) 2,23, 0.83) 3,49, 0.83) 3,58, 1.09) 3,58, 1.09) 3,58, 1.09) 3,58, 0.98) 3,58, 0.98) 3,70, 1.16) 3,70, 1.20 3,80, 0.83) 3,80, 0.84) 3,80, 0.84) 3,80, 0.84) 3,80, 0.85) 3,80, 0.85)	% Weight 6.54 7.63 14.17 5.68 5.68 13.93 13.93 13.93 12.41 12.41 0.69 0.69 14.02 14.02 14.22 14.22 13.21 13.21 1.84 9.83 9.63 10.000

FIGURE 4 | Survival influences of FLT3i on FLT3(+) rrAML. (A) Pooled HR and 95% Cl of all FLT3i during salvage therapy in FLT3(+) rrAML for OS, EFS, and RFS; (B) Pooled HR and 95% Cl of each FLT3i during salvage therapy in FLT3(+) rrAML for OS, EFS, and RFS. FLT3, FMS-like tyrosine kinase 3; FLT3i, FLT3 inhibitor; AML, acute myeloid leukemia; rrAML, refractory and relapsed AML; OS, overall survival; EFS, event-free survival; RFS, relapse-free survival; HR, hazard ratio; 95% Cl, 95% confidence interval.

Sensitivity Analyses and Publication Bias

Sensitivity analyses were conducted if high heterogeneity (P < 0.10) existed. The heterogeneity sources were listed in **Supplementary Table 4**, which were related to age, various FLT3i, allo-HSCT, cytogenetics, and genetics. **Supplementary Table 8** displayed the publication bias in RFS of FLT3i in induction stage, OS and RFS of allo-HSCT in *FLT3*(+) AML,

as well as OS of FLT3i in salvage regimen. The funnel plots were illustrated in **Supplementary Figures 6–10**.

Network Meta-Analyses

Supplementary Figures 11A–D showed the network evidence plots for comparing CR, OS, EFS, and RFS between various FLT3i in AML, noting the lack of head-to-head trial except for



FIGURE 5 | Response to FLT3i during induction/reinduction treatment of newly diagnosed AML and FLT3(+) rrAML. (A) Pooled RR and 95% CI of all FLT3i during induction treatment and salvage regimen for CR; (B) Pooled RR and 95% CI of each FLT3i during induction treatment and salvage regimen for CR. FLT3, FMS-like tyrosine kinase 3; FLT3i, FLT3 inhibitor; AML, acute myeloid leukemia; rrAML, refractory and relapsed AML; CR, complete remission; RR, relative risk; 95% CI, 95% confidence interval.

analyses of OS and RFS. Consequently, for EFS and CR, the summarized data between interventions were produced either from qualified indirect or direct evidence but not from both, without ability to estimate the inconsistency between direct and indirect comparisons. Regarding all endpoints included in NMA, gilteritinib accomplished a tendency of the best prognosis compared with standard chemotherapy, particularly in CR (RR 0.45, 95% Crl 0.20-1.10) and OS (HR 0.64, 95% Crl 0.39-1.00) (**Supplementary Figures 11E–H**), and also favored the highest probability of

OS, high Tatio 0.58 (0.88, 0.97) 12.43 Orran 2020 40 43 0.69 (0.45, 1.05) 0.60 Stone 2017 108 106 0.88 (0.80, 0.97) 12.43 Stone 2017 108 106 0.60 0.60 Krapper 2017 132 25 0.60 0.88 (0.80, 0.97) 12.43 Subtotal (I-squared = 0.0%, p = 0.654) 0.80 (0.57, 1.12) 0.44 0.45 0.88 (0.79, 0.94) 14.19 Orran 2020 25 21 0.69 (0.45, 1.05) 0.60 Cortes 2019 86 42 0.69 (0.45, 1.05) 0.60 Cortes 2019 86 42 0.88 (0.60, 0.71, 0.94) 1.419 Stone 2017 73 53 0.88 (0.69, 0.99) 1.31 Krapper 2017 73 53 0.80 (0.61, 0.11) 1.13 Krapper 2017 30 23 0.92 (0.85, 0.99) 18.47 Krapper 2017 30 23 0.92 (0.85, 0.99) 18.47 Krapper 2017	OC hist and			
Cortain 200 a0 -3 0.58 (0.60, 0.45, 1.05) 0.60 Stone 2017 108 106 0.80 (0.57, 1.12) 0.94 Krapper 2017 32 25 0.86 (0.79, 0.94) 14.19 Subtotal (I-squared = 0.0%, p = 0.654) 0.86 (0.79, 0.94) 14.19 Cortes 2019 86 42 Offan 2020 25 21 0.66 (0.57, 1.12) 0.60 Cortes 2019 86 42 0.69 (0.45, 1.05) 0.60 Cortes 2019 86 42 0.69 (0.45, 1.05) 0.60 Cortes 2019 86 42 0.69 (0.45, 1.05) 0.60 Cortes 2019 86 42 0.88 (0.54, 1.44) 0.45 Stone 2017 73 53 0.76 (0.47, 1.22) 0.47 Subtotal (I-squared = 0.0%, p = 0.807) 0.83 (0.69, 0.99) 18.47 0.76 (0.47, 1.22) 0.47 Subtotal (I-squared = 0.0%, p = 0.368) 0.92 (0.85, 0.99) 18.68 0.92 (0.85, 0.99) 18.68 r r 0.77 (0.71, 1.03 0.66 0	Os, nign ratio		0 88 (0 80 0 87)	12.42
Cortes 2017 108 106 Stone 2017 108 106 Krapper 2017 32 25 Subtotal (I-squared = 0.0%, p = 0.654) 0.86 (0.77, 0.94) 14.19 0.5 0.65 (0.67, 1.12) 0.94 Ofran 2020 25 1 0.86 (0.77, 0.94) 14.19 0.5 0.65 (0.67, 1.02) 0.94 0.88 (0.57, 1.02) 0.94 Orran 2020 25 21 0.74 (0.37, 1.47) 0.23 Orran 2020 25 21 0.94 0.94 Orran 2020 25 1 0.66 (0.57, 1.02) 0.66 Cortes 2019 66 37 0.81 (0.60, 0.111) 1.13 Krapper 2017 115 69 0.81 (0.60, 0.111) 1.13 Krapper 2017 30 23 0.66 (0.32, 1.35) 0.21 Burchert 2020 24 25 0.92 (0.85, 0.99) 18.47 Krapper 2017 102 66 0.82 (0.67, 1.22) 0.70 </td <td>Cortes 2019 90 43</td> <td></td> <td>0.69 (0.45, 1.05)</td> <td>0.60</td>	Cortes 2019 90 43		0.69 (0.45, 1.05)	0.60
Krapper 2017 32 25 0.74 (0.37, 147) 0.23 Subtotal (I-squared = 0.0%, p = 0.654) 0.86 (0.79, 0.94) 14.19 OS, low ratio 0.52 (0.99, 25.17) 0.01 Ortra 2020 25 21 0.66 (0.79, 0.94) 14.19 OS, low ratio 0.69 (0.45, 1.05) 0.60 Cortes 2019 66 37 0.88 (0.54, 1.44) 0.45 Stone 2017 171 170 0.88 (0.54, 1.44) 0.46 Krapper 2017 135 59 0.76 (0.47, 1.22) 0.47 Subtotal (I-squared = 0.0%, p = 0.807) 0.83 (0.69, 0.99) 3.31 Instruct 2020 24 25 0.92 (0.85, 0.99) 18.47 Krapper 2017 30 23 0.97 (0.93, 1.01) 59.62 Subtotal (I-squared = 0.0%, p = 0.368) 0.97 (0.93, 1.01) 59.62 Nrapper 2017 102 66 13 0.97 (0.93, 1.01) 59.62 Krapper 2017 102 66 0.97 (0.93, 1.01) 59.62 Krapper 2017 108 106 0.77 (0.57, 1.04) 1.19 Subtotal (I-squared = 0.0%, p = 0.483) 0.77 (0.57, 1.04) 1.19 IFS, high ratio 0.85 (0.67, 1.09) 1.81 Stone 2017 171 170 0.85 (0.67, 1.08) 1.81 Subtotal (I-	Stone 2017 108 106	<u> </u>	0.80 (0.57, 1.12)	0.94
Subtotal (I-squared = 0.0%, p = 0.654) 0.86 (0.79, 0.94) 14.19 Ofran 2020 25 21 Ortes 2019 86 42 Octres 2019 86 42 Octres 2019 66 37 Stone 2017 171 170 Krapper 2017 73 53 Subtotal (I-squared = 0.0%, p = 0.807) 0.88 (0.69, 1.56) 0.64 Nrapper 2017 73 53 Burchert 2020 24 25 Krapper 2017 30 23 Subtotal (I-squared = 0.0%, p = 0.368) 0.92 (0.85, 0.99) 18.47 Nrapper 2017 30 23 0.66 (0.32, 1.38) 0.21 Subtotal (I-squared = 0.0%, p = 0.368) 0.97 (0.93, 101) 59.62 0.84 (0.57, 1.29) 0.86 RFS, low ratio 0.97 (0.93, 101) 59.62 0.77 (0.49, 1.23) 0.51 Burchert 2020 16 13 0.97 (0.93, 101) 60.82 0.97 (0.93, 101) 60.82 FS, high ratio Subtotal (I-squared = 0.0%, p = 0.483) <t< td=""><td>Krapper 2017 32 25</td><td>•</td><td>0.74 (0.37, 1.47)</td><td>0.23</td></t<>	Krapper 2017 32 25	•	0.74 (0.37, 1.47)	0.23
OS, low ratio Ofran 2020 25 21 Octres 2019 86 42 Cortes 2019 86 37 Stone 2017 171 170 Krapper 2017 73 53 Subtotal (I-squared = 0.0%, p = 0.487) 0.69 0.69 Burchert 2020 24 25 Krapper 2017 30 23 Subtotal (I-squared = 0.0%, p = 0.483) 0.21 0.22 0.292 0.85, 0.99) 18.68 RFS, high ratio 0.92 0.85, 0.99) 18.68 <td>Subtotal (I-squared = 0.0%, p = 0.654)</td> <td>0</td> <td>0.86 (0.79, 0.94)</td> <td>14.19</td>	Subtotal (I-squared = 0.0%, p = 0.654)	0	0.86 (0.79, 0.94)	14.19
Ofran 2020 25 21 Cortes 2019 86 42 Cortes 2019 66 37 Stone 2017 171 170 Krapper 2017 173 53 Subtotal (I-squared = 0.0%, p = 0.807) 0.88 (0.64, 1.44) 0.45 Burchert 2020 24 25 RFS, high ratio 0.92 (0.85, 0.99) 18.47 Burchert 2020 24 25 RFS, high ratio 0.92 (0.85, 0.99) 18.47 Subtotal (I-squared = 0.0%, p = 0.368) 0.92 (0.85, 0.99) 18.47 Nrapper 2017 30 23 0.66 (0.32, 1.38) 0.21 Subtotal (I-squared = 0.0%, p = 0.368) 0.92 (0.85, 0.99) 18.68 0.97 (0.93, 1.01) 59.62 Krapper 2017 172 66 0.77 (0.49, 1.23) 0.51 Subtotal (I-squared = 0.0%, p = 0.483) 0.97 (0.93, 1.01) 60.82 0.77 (0.57, 1.04) 1.19 Stone 2017 108 106 0.77 (0.57, 1.04) 1.19 Stone 2017 171	OS, low ratio	1		
Cortes 2019 86 42 0.69 0.45, 10.5) 0.60 Cortes 2019 66 37 0.88 0.54, 1.44) 0.45 Stone 2017 171 170 0.81 0.60 0.45, 10.5) 0.64 Krapper 2017 115 69 1.04 (0.69, 1.56) 0.64 Krapper 2017 3 53 0.76 (0.47, 1.22) 0.47 Subtotal (I-squared = 0.0%, p = 0.807) 0.83 0.89 0.99 9.33 Rrs, high ratio Burchert 2020 24 25 . 0.92 (0.85, 0.99) 18.47 Krapper 2017 30 23 Subtotal (I-squared = 0.0%, p = 0.368) Burchert 2020 13 <	Ofran 2020 25 21	 ◆	▶ 1.52 (0.09, 25.17)	0.01
Cortes 2019 66 37 0.88 (0.54, 1.44) 0.45 Stone 2017 171 170 0.81 (0.60, 1.11) 1.13 Krapper 2017 73 53 0.76 (0.47, 1.22) 0.47 Subtotal (I-squared = 0.0%, p = 0.807) 0.83 (0.69, 0.99) 3.31 RFS, high ratio Burchert 2022 (2.85, 0.99) 18.47 Krapper 2017 30 23 0.66 (0.32, 1.35) 0.21 Subtotal (I-squared = 0.0%, p = 0.368) 0.92 (0.85, 0.99) 18.47 Krapper 2017 30 23 0.66 (0.32, 1.35) 0.21 Subtotal (I-squared = 0.0%, p = 0.368) 0.97 (0.93, 1.01) 59.62 0.87 (0.93, 1.01) 59.62 Krapper 2017 102 66 0.84 (0.57, 1.25) 0.70 0.77 (0.49, 1.23) 0.51 Subtotal (I-squared = 0.0%, p = 0.483) 0.97 (0.93, 1.01) 60.82 0.97 (0.93, 1.01) 60.82 0.77 (0.57, 1.04) 1.19	Cortes 2019 86 42		0.69 (0.45, 1.05)	0.60
Stone 2017 171 170 0.81 (0.60, 1.11) 1.13 Krapper 2017 15 69 1.04 (0.69, 1.56) 0.64 Krapper 2017 73 53 0.76 (0.47, 1.22) 0.47 Subtotal (I-squared = 0.0%, p = 0.807) 0.83 (0.69, 0.99) 3.31 0.92 (0.85, 0.99) 18.47 Burchert 2020 24 25 0.92 (0.85, 0.99) 18.47 Krapper 2017 30 23 0.66 (0.32, 1.35) 0.21 Subtotal (I-squared = 0.0%, p = 0.368) 0.92 (0.85, 0.99) 18.68 Subtotal (I-squared = 0.0%, p = 0.483) 0.97 (0.93, 1.01) 59.62 Krapper 2017 66 Subtotal (I-squared = 0.0%, p = 0.483) 0.97 (0.93, 1.01) 60.82 Stone 2017 171 170	Cortes 2019 66 37	•	0.88 (0.54, 1.44)	0.45
Krapper 2017 115 69 1.04 (0.69, 1.56) 0.64 Krapper 2017 73 53 0.76 (0.047, 1.22) 0.47 Subtotal (I-squared = 0.0%, p = 0.807) 0.83 (0.69, 0.99) 3.31 . . . RFS, high ratio Burchert 2020 24 25 0.92 (0.85, 0.99) 18.47 Krapper 2017 30 23 0.66 (0.32, 1.35) 0.21 Subtotal (I-squared = 0.0%, p = 0.568) 0.92 (0.85, 0.99) 18.47 Burchert 2020 16 13 0.97 (0.93, 1.01) 59.62 Krapper 2017 70 2 66 0.97 (0.93, 1.01) 59.62 Krapper 2017 70 75 50 0.70 0.77 (0.49, 1.23) 0.51 Subtotal (I-squared = 0.0%, p = 0.483) 0.97 (0.93, 1.01) 60.82 0.97 (0.93, 1.01) 60.82 0.97 (0.93, 1.01) 60.82 0.77 (0.57, 1.04) 1.19 Subtotal (I-squared = 0.0%, p =) 0.77 (0.57, 1.04) 1.19 0.85 (0.67, 1.09) 1.81 <	Stone 2017 171 170		0.81 (0.60, 1.11)	1.13
Krapper 2017 73 53 0.76 (0.47, 1.22) 0.47 Subtotal (I-squared = 0.0%, p = 0.807) 0.83 (0.69, 0.99) 3.31 RFS, high ratio . . . Burchert 2020 (285, 0.99) 18.47 Krapper 2017 30 23 Subtotal (I-squared = 0.0%, p = 0.368) 0.97 (0.93, 1.01) 59.62 RFS, low ratio . . . Burchert 2020 16 13 . . Krapper 2017 102 66 . . . Burchert 2020 16 13 . . . Subtotal (I-squared = 0.0%, p = 0.483) Stone 2017 108 106 Stone 2017 171 170 Stone 2017 171 170 Subtotal (I-squared = .%,	Krapper 2017 115 69	•	1.04 (0.69, 1.56)	0.64
Subtotal (I-squared = 0.0%, p = 0.807) 0.83 (0.69, 0.99) 3.31 RFS, high ratio 0.92 (0.85, 0.99) 18.47 Burchert 2020 24 25 0.92 (0.85, 0.99) 18.47 Krapper 2017 30 23 0.92 (0.85, 0.99) 18.68 RFS, low ratio 0.97 (0.93, 1.01) 59.62 Burchert 2020 16 13 0.97 (0.93, 1.01) 59.62 Krapper 2017 102 66 0.77 (0.49, 1.23) 0.51 Subtotal (I-squared = 0.0%, p = 0.483) 0.97 (0.93, 1.01) 60.82 EFS, high ratio . . . Stone 2017 108 106 . . . Stone 2017 171 170 . . . Stone 2017 171 170 . . . Stone 2017 171 170 </td <td>Krapper 2017 73 53</td> <td></td> <td>0.76 (0.47, 1.22)</td> <td>0.47</td>	Krapper 2017 73 53		0.76 (0.47, 1.22)	0.47
RFS, high ratio 0.92 (0.85, 0.99) 18.47 Burchert 2020 24 25 0.96 (0.32, 1.35) 0.21 Subtotal (I-squared = 0.0%, p = 0.368) 0.92 (0.85, 0.99) 18.68 RFS, low ratio 0.97 (0.93, 1.01) 59.62 Burchert 2020 16 13 0.97 (0.93, 1.01) 59.62 Krapper 2017 67 50 0.77 (0.49, 1.23) 0.51 Subtotal (I-squared = 0.0%, p = 0.483) 0.97 (0.93, 1.01) 60.82 I I 0.97 (0.93, 1.01) 60.82 I 0.97 (0.93, 1.01) 60.82 0.97 (0.93, 1.01) Subtotal (I-squared = 0.0%, p = 0.483) 0.97 (0.93, 1.01) 60.82 I I 0.97 (0.57, 1.04) 1.19 Subtotal (I-squared = .%, p = .) 0.77 (0.57, 1.04) 1.19 I I 0.85 (0.67, 1.09) 1.81 Overall (I-squared = .%, p = .) 0.93 (0.90, 0.96) 100.00	Subtotal (I-squared = 0.0%, p = 0.807)		0.83 (0.69, 0.99)	3.31
bit life 1 2020 24 2.5 Krapper 2017 30 23 Subtotal (I-squared = 0.0%, p = 0.368) 0.92 (0.35, 0.39) 18.68 RFS, low ratio 0.92 (0.35, 0.39) 18.68 Burchert 2020 16 13 Burchert 2020 16 13 Burchert 2021 10 59.62 Krapper 2017 67 50 Subtotal (I-squared = 0.0%, p = 0.483) 0.97 (0.93, 1.01) 69.82 EFS, high ratio . . . Stone 2017 108 106 Stone 2017 171 170 Stone 2017 171 170 Stone 2017 131 <t< td=""><td>RFS, high ratio</td><td></td><td>0.02 (0.85, 0.00)</td><td>10.47</td></t<>	RFS, high ratio		0.02 (0.85, 0.00)	10.47
Napper 2017 30 25 25 0.58 (0.52, 1.53) 0.21 Subtotal (I-squared = 0.0%, p = 0.483) 0.97 (0.93, 1.01) 59.62 Image: RFS, low ratio 0.97 (0.93, 1.01) 59.62 Burchert 2020 16 13 0.97 (0.93, 1.01) 59.62 Krapper 2017 102 66 0.77 (0.49, 1.23) 0.51 Subtotal (I-squared = 0.0%, p = 0.483) 0.97 (0.93, 1.01) 60.82 FS, high ratio 0.77 (0.57, 1.04) 1.19 Subtotal (I-squared = .%, p = .) 0.77 (0.57, 1.04) 1.19 	Burchert 2020 24 25		0.66 (0.22, 1.25)	18.47
Junctar (=squared = 0.0%, p = 0.305) 0.32 (0.53, 0.59) 18.08 Image: RFS, low ratio 0.97 (0.93, 1.01) 59.62 Burchert 2020 16 13 0.97 (0.93, 1.01) 59.62 Krapper 2017 67 50 0.77 (0.49, 1.23) 0.51 Subtotal (I-squared = 0.0%, p = 0.483) 0.97 (0.93, 1.01) 60.82 Image: RFS, high ratio 0.77 (0.57, 1.04) 1.19 Stone 2017 108 106 0.77 (0.57, 1.04) 1.19 Subtotal (I-squared = .%, p = .) 0.77 (0.57, 1.04) 1.19 Image: RFS, low ratio 0.85 (0.67, 1.09) 1.81 Subtotal (I-squared = .%, p = .) 0.85 (0.67, 1.08) 1.81 Overall (I-squared = 0.0%, p = 0.458) 0.93 (0.90, 0.96) 100.00	Number 2017 SU 25 Subtotal (Licauarad = 0.0% p = 0.26%)		0.02 (0.85, 0.00)	10.00
RFS, low ratio 0.97 (0.93, 1.01) 59.62 Burchert 2020 16 13 0.97 (0.93, 1.01) 59.62 Krapper 2017 102 66 0.84 (0.57, 1.25) 0.70 Krapper 2017 67 50 0.77 (0.49, 1.23) 0.51 Subtotal (I-squared = 0.0%, p = 0.483) 0.97 (0.93, 1.01) 60.82 EFS, high ratio 510e 0.77 (0.57, 1.04) 1.19 Subtotal (I-squared = .%, p = .) 0.77 (0.57, 1.04) 1.19 Stone 2017 171 170 0.85 (0.67, 1.09) 1.81 Subtotal (I-squared = .%, p = .) Overall (I-squared = 0.0%, p = 0.458) . 0.93 (0.90, 0.96) 100.00			0.52 (0.85, 0.55)	18.08
Krapper 2017 102 66 0.84 (0.57, 1.25) 0.70 Krapper 2017 67 50 0.77 (0.49, 1.23) 0.51 Subtotal (I-squared = 0.0%, p = 0.483) 0.97 (0.33, 1.01) 60.82 EFS, high ratio 0.77 (0.57, 1.04) 1.19 Subtotal (I-squared = .%, p = .) 0.77 (0.57, 1.04) 1.19 0.77 (0.57, 1.04) 1.19 0.77 (0.57, 1.04) 1.19 0.77 (0.57, 1.04) 1.19 0.77 (0.57, 1.04) 1.19 0.85 (0.67, 1.09) 1.81 0.85 (0.67, 1.09) 1.81 0.85 (0.67, 1.08) 1.81 0.93 (0.90, 0.96) 100.00	RFS, low ratio Burchert 2020 16 13		0.97 (0.93, 1.01)	59.62
Krapper 2017 67 50 0.77 (0.49, 1.23) 0.51 Subtotal (I-squared = 0.0%, p = 0.483) 0.97 (0.93, 1.01) 60.82 EFS, high ratio 0.77 (0.57, 1.04) 1.19 Stotectal (I-squared = .%, p = .) 0.77 (0.57, 1.04) 1.19 EFS, low ratio 0.85 (0.67, 1.09) 1.81 Stotectal (I-squared = .%, p = .) 0.85 (0.67, 1.08) 1.81 Overall (I-squared = 0.0%, p = 0.458) 0.93 (0.90, 0.96) 100.00	Krapper 2017 102 66		0.84 (0.57, 1.25)	0.70
Subtotal (I-squared = 0.0%, p = 0.483) 0.97 (0.93, 1.01) 60.82 EFS, high ratio 0.77 (0.57, 1.04) 1.19 Stototal (I-squared = .%, p = .) 0.77 (0.57, 1.04) 1.19 EFS, how ratio 0.77 (0.57, 1.04) 1.19 Stototal (I-squared = .%, p = .) 0.85 (0.67, 1.09) 1.81 Overall (I-squared = .0.%, p = 0.458) 0.93 (0.90, 0.96) 100.00	Krapper 2017 67 50	_	0.77 (0.49, 1.23)	0.51
Image: FS, high ratio 0.77 (0.57, 1.04) 1.19 Stone 2017 108 106 Subtotal (I-squared = .%, p = .) 0.77 (0.57, 1.04) 1.19 Image: FS, high ratio 0.77 (0.57, 1.04) 1.19 Subtotal (I-squared = .%, p = .) 0.85 (0.67, 1.09) 1.81 Overall (I-squared = 0.0%, p = 0.458) 0.93 (0.90, 0.96) 100.00	Subtotal (I-squared = 0.0%, p = 0.483)	¢	0.97 (0.93, 1.01)	60.82
Stone 2017 108 106 0.77 (0.57, 1.04) 1.19 Subtotal (I-squared = .%, p = .) 0.77 (0.57, 1.04) 1.19 . . 0.77 (0.57, 1.04) 1.19 Subtotal (I-squared = .%, p = .) 0.85 (0.67, 1.09) 1.81 . 0.85 (0.67, 1.08) 1.81 . 0.93 (0.90, 0.96) 100.00	EFS, high ratio			
Subtotal (I-squared = .%, p = .) EFS, low ratio Stone 2017 171 170 Subtotal (I-squared = .%, p = .) Overall (I-squared = 0.0%, p = 0.458) Subtotal (I-squared = 0.0%, p = 0.458) Overall (I-squared = 0.0%, p = 0.458)	Stone 2017 108 106		0.77 (0.57, 1.04)	1.19
EFS, low ratio 0.85 (0.67, 1.09) 1.81 Stototal (I-squared = .%, p = .) 0.85 (0.67, 1.08) 1.81 Overall (I-squared = 0.0%, p = 0.458) 0.93 (0.90, 0.96) 100.00	Subtotal (I-squared = .%, p = .)	\diamond	0.77 (0.57, 1.04)	1.19
Storie 2017 171 170 0.53 (0.67, 1.08) 1.81 Subtotal (I-squared = %, p = .) 0.85 (0.67, 1.08) 1.81 Overall (I-squared = 0.0%, p = 0.458) 0.93 (0.90, 0.96) 100.00	EFS, low ratio		0.85 (0.67, 1.00)	1.01
Subtrail (=squared = .%, p = .) 0.83 (0.07, 1.06) 1.81 Overall (I=squared = 0.0%, p = 0.458) 0.93 (0.90, 0.96) 100.00	Subtotal /L caused = 9(p =)	\mathbf{x}	0.85 (0.67, 1.09)	1.01
Overall (I-squared = 0.0%, p = 0.458) 0.93 (0.90, 0.96) 100.00	Subtotal (I-squared = :%, p = .)		0.85 (0.67, 1.08)	1.81
	Overall (I-squared = 0.0%, p = 0.458)	0	0.93 (0.90, 0.96)	100.00
NOTE: Weights are from random effects analysis	NOTE: Weights are from random effects analysis			

FIGURE 6 | Survival effectiveness of FLT3i to the *FLT3-ITD* allelic ratio. Except for the study from Stone et al. (3), high ratio was identified as \geq 0.5 as shown in the **Supplementary Table 6**. In the study from Stone et al. (3), high ratio was regarded as >0.7. FLT3, FMS-like tyrosine kinase 3; FLT3i, FLT3 inhibitor; *FLT3-ITD*, FMS-like tyrosine kinase 3-internal tandem duplication; OS, overall survival; EFS, event-free survival; RFS, relapse-free survival; HR, hazard ratio; 95% CI, 95% confidence interval.

improving prognosis (**Supplementary Figures 111–L**) when compared to other strategies. The detailed results of prognostic effects from all treatments were presented in **Supplementary Tables 9–12**. The results of node splitting method exhibited no inconsistency between indirect and direct evidence for OS and RFS (**Supplementary Figure 12**). No heterogeneity was found in all NMA, except for pooled RR of CR and HR of EFS from studies of Roellig et al. (7) and Serve et al. (21) (**Supplementary Figure 13**). The heterogeneity reason is that ages of AML patients from Roellig et al. (7) were aged 60 years or younger, but it was opposite in Serve et al. (21).

DISCUSSION

Until now, no consensus was present on FLT3i role in various AML treatment stages, especially for *FLT3*(+) AML, and which FLT3i might be the best, which were investigated in this study. FLT3i possibly supported better CR in induction and salvage therapy that further boosted the improved survival of FLT3i. Allo-HSCT improved survival in *FLT3*(+) AML and FLT3i as the maintenance therapy after allo-HSCT might further enhance survival benefit gained from allo-HSCT. FLT3i also improved OS regardless of stratification of *FLT3-ITD* ratio, when compared to non-FLT3i group. Additionally, FLT3i consistently showed significantly increased risk of thrombocytopenia, neutropenia, anemia,

skin-related adverse effects, increased alanine aminotransferase, cardiac-related adverse events, cough and dyspnea, but were not associated with high early death and increased risk of GVHD. NMA showed that gilteritinib probably favored the highest possibility toward better prognosis, which should be identified in more direct head-to-head RCT.

The summarized data in induction stage favored the prognostic benefit from FLT3i in AML, especially for sorafenib and midostaurin, consistent with a preceding RCT. Roellig et al. (7), one of the largest two RCT of sorafenib, reported improved EFS and RFS of sorafenib in patients aged ≤ 60 years. A possible mechanism underlying these data even in wild-type FLT3 was the antileukemic activity of sorafenib in inhibiting other kinases such as RAF (24), KIT, platelet-derived growth factor receptors, and vascular endothelial growth factor receptors (7). In contrast, Serve et al. (21), another largest RCT for sorafenib, exhibited a higher early mortality and increased toxicity without improved antileukemic efficacy of sorafenib in patients \geq 60 years. The plausible explanation was the lower tolerability of elderly patients for sorafenib, as well as overexpressed multidrug-resistant phenotypes and, probably, more epigenetic changes in elderly cohorts (25), which offset the targeting effect of sorafenib for FLT3 and contributed to the heterogeneity of summarized EFS in induction stage in our study. For midostaurin, a large RCT (RATIFY) (3) reported that among FLT3(+) patients aged 18-59 years, midostaurin plus chemotherapy achieved prolonged

Effects of FLT3i in AML

survival, regardless of *FLT3-TKD* and different levels of mutant *FLT3-ITD* ratio, probably resulting from enough exposure to this inhibitor. Given a benefit among patients with low allelic *FLT3-ITD* mutation and a large disease burden, the benefit of this multitargeted kinase inhibitor might lie beyond its ability to inhibit *FLT3*, like inhibiting *KIT* in *FLT3* (–) AML (3). Finally, Knapper et al. (10) confirmed that lestaurtinib + chemotherapy had no enhanced prognosis among younger *FLT3*(+) AML, possibly due to the rising level of *FLT3* ligand induced by chemotherapy, which could interfere with activity of *FLT3* inhibition, including lestaurtinib (10).

Next, allo-HSCT possibly also enhanced survival in FLT3(+) AML. However, some variables greatly affect the effectiveness of allo-HSCT, including disease status (CR or not), FLT3 variables (allelic burden and co-mutations), and using FLT3i before and/ or after allo-HSCT. Unfortunately, no RCT assessed the most suitable post-remission treatment in FLT3(+) AML, considering diverse combinations (26). However, we herein summarized the maintenance effects of FLT3i following allo-HSCT, since even after allo-HSCT, early relapse frequently occurred in FLT3(+) AML (30%-59%) (27). Indeed, increased survival was observed in FLT3i as the maintenance therapy after allo-HSCT, especially for sorafenib. Similarly, one recent phase 3 RCT (28) showed enhanced survival and high tolerance of sorafenib, identifying safety and availability of sorafenib after allo-HSCT. Moreover, in a large retrospective study including 144 FLT3-ITD(+) patients undergoing allo-HSCT (22), probability of CIR and OS was the best in sorafenib administrated both before and after allo-HSCT compared to either alone and non-sorafenib group. Based on these results, further clinical trials should be determined to directly compare availability between four arms above. Besides, sorafenib, midostaurin and gilteritinib were currently evaluated for maintaining after allo-HSCT in FLT3-ITD(+) AML. In the RADIUS phase 2 RCT (29), midostaurin achieved a slight tendency of better OS and CIR. Gilteritinib is prospectively estimated in a phase 3 RCT (NCT02997202). Overall, for the foreseeable future, FLT3(+) AML patients may still benefit from sorafenib after allo-HSCT because of the less use of other FLT3i (26).

Due to high refractory and relapse incidence in *FLT3*(+) AML (6) and limited knowledge to treat FLT3(+) rrAML, we also explored consistent or different therapeutic efficiency between various FLT3i in such patients. Except for lestaurtinib, the combined OS could be consistently improved by sorafenib, gilteritinib, and quizartinib, showing the potential of FLT3i in treating FLT3(+) rrAML. A phase 3 RCT randomized 371 FLT3(+) rrAML to either gilteritinib or salvage chemotherapy (6), showing increased survival as well as decreased frequency of adverse events in gilteritinib. Results from a similar phase 3 RCT (QuANTUM-R) comparing quizartinib with salvage chemotherapy in 367 FLT3(+) rrAML patients also confirmed quizartinib availability in improving prognosis (p < 0.05). Until now, the promising efficiency of gilteritinib and quizartinib could be observed in *FLT3*(+) rrAML in the two large RCT. However, a lack of evidence is present to add the two FLT3i to induction, consolidation, and maintenance therapy after allo-HSCT.

Several phase 2 or 3 RCT are being processed (Gilteritinib: NCT02927262, NCT02997202, and NCT02752035; Quizartinib: NCT02668653). Additionally, two retrospective studies of sorafenib from Bazarbachi et al. (30) and Xuan et al. (31) also revealed enhanced OS comparing sorafenib with salvage chemotherapy in *FLT3*(+) rrAML, which should be further confirmed in RCT. Finally, midostaurin might be specifically effective in the untreated AML rather than rrAML, since *in vitro* studies, midostaurin had broader activity and might achieve greater clinical utility in newly diagnosed AML with blasts tending to be less addicted to *FLT3*-mediated signaling than rrAML (32).

We also explored the effectiveness of FLT3i on FLT3-ITD(+) AML stratified by ITD allelic ratios, showing that FLT3i consistently achieved significantly improved OS in both of high and low ratio crossing sorafenib, quizartinib, midostaurin and even lestaurtinib, further suggesting the benefits of FLT3i in FLT3-ITD(+) AML. However, there was no information involved in assessing clinical efficiency of gilteritinib in patients with different levels of FLT3-ITD ratio, which needs to be further explored in more studies.

For adverse events, FLT3i were significantly associated with increased risk of thrombocytopenia, neutropenia and anemia regardless of grades, high risk of skin- and cardiac-related adverse effects, especially for grades \geq 3, all-grade increased alanine aminotransferase, high risk of all-grade cough and dyspnea, as well as a tendency of increased risk for all-grade gastrointestinal-related toxicities. However, these adverse events were generally manageable based on treatment interruptions or dose reductions (2). Moreover, there was no significant relationship between FLT3i as well as high early death and high risk of GVHD, demonstrating the safety of FLT3i.

Finally, due to co-existence of several FLT3i, it would also be meaningful to explore which inhibitor might be the best. Herein, we finished an NMA based on all RCT to settle this problem. The results displayed that gilteritinib probably tended to favor the highest probability of improving prognosis compared with other FLT3i, standard of care and standard chemotherapy. The relevant RCT involved in gilteritinib for rrAML treatment also illustrated improved survival as mentioned above (6). However, these results and corresponding consequences were relatively limited, given the rather small improvement obtained which each FLT3i through the indirect comparison. More direct headto-head RCT with large cohort size are required to explore the different clinical efficiency between these FLT3i.

Overall, our study was up to now the biggest and the most comprehensive meta-analysis involved in various FLT3i in AML, containing all RCT and retrospective cohort studies. In addition to FLT3i function in induction stage in untreated AML, the role of allo-HSCT in *FLT3*(+) AML and therapeutic efficiency of FLT3i as maintenance therapy after allo-HSCT and as salvage regimens in rrAML were summarized and explored, showing that combining FLT3i, especially sorafenib, into the treatment before and after allo-HSCT might be more beneficial in improving prognosis, which should be further explored in RCT. Our study also primitively proposed NMA to compare various FLT3i, but with limitations as mentioned above. There were also several limitations in this study. Of 39 studies, 28 studies were retrospective, making it difficult to precisely control selection, attrition, information and confounding bias. In particular, due to RCT lack, limited results and conclusion were obtained from NMA. Besides, some data were extracted from Kaplan-Meier survival curves and numeric reports, probably resulting in slight disparity with the fact. Finally, this study did not make subgroup analyses based on age, co-existing mutations with *FLT3* mutations, and cytogenetic stratifications due to limited relevant data in primary studies. As a consequence, we will continue updating this study to explore suitable treatment of FLT3i in AML patients.

CONCLUSIONS

In this work, FLT3i reinforced better prognosis in the induction stage of newly diagnosed FLT3(+) AML and salvage therapy of FLT3(+) rrAML and further enhanced survival advantages from allo-HSCT as the maintenance therapy. This probably indicates that better prognosis could be achieved if FLT3i is added into both treatments before and after allo-HSCT. Besides, FLT3i probably improved OS regardless of FLT3-ITD ratio. Additionally, FLT3i were significantly linked to increased risk of all-grade thrombocytopenia, neutropenia, anemia, all-grade skin- and cardiac-related adverse effects, especially for grade \geq 3, as well as all-grade increased alanine aminotransferase, enhanced risk of allgrade cough and dyspnea, and a tendency of increased risk for allgrade gastrointestinal-related toxicities, but not related to higher incidence of early death and GVHD compared to non-FLT3i group. In NMA, gilteritinib potentially accomplished the best prognosis, which should be identified in direct head-to-head RCT.

REFERENCES

- Grove CS, Vassiliou GS. Acute Myeloid Leukaemia: A Paradigm for the Clonal Evolution of Cancer? *Dis Model Mech* (2014) 7:941–51. doi: 10.1242/ dmm.015974
- Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 Mutations in AML: Review of Current Knowledge and Evidence. *Leukemia*. (2019) 33:299– 312. doi: 10.1038/s41375-018-0357-9
- Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin Plus Chemotherapy for Acute Myeloid Leukemia With a FLT3 Mutation. N Engl J Med (2017) 377:454–64. doi: 10.1056/ NEJMoa1614359
- Grafone T, Palmisano M, Nicci C, Storti S. An Overview on the Role of FLT3tyrosine Kinase Receptor in Acute Myeloid Leukemia: Biology and Treatment. Oncol Rev (2012) 6:e8. doi: 10.4081/oncol.2012.e8
- Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, et al. Quizartinib Versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukaemia (QuANTUM-R): A Multicentre, Randomised, Controlled, Open-Label, Phase 3 Trial. *Lancet Oncol* (2019) 20:984–97. doi: 10.1016/S1470-2045(19)30150-0
- Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated Aml. N Engl J Med (2019) 381:1728–40. doi: 10.1056/NEJMoa1902688
- Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, et al. Addition of Sorafenib Versus Placebo to Standard Therapy in Patients Aged 60 Years or Younger With Newly Diagnosed Acute Myeloid Leukaemia (SORAML): A Multicentre, Phase 2, Randomised Controlled Trial. *Lancet Oncol* (2015) 16:1691–9. doi: 10.1016/S1470-2045(15)00362-9

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/**Supplementary Material**. Further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

QX and LY contributed to conception and design of the study. QX and SH collected data from database. QX and SH performed the statistical analyses. QX and LY wrote the first draft of the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by Chinese National Major Project for New Drug Innovation (2019ZX09201002003), National Natural Science Foundation of China (82030076, 82070161, 81970151, 81670162 and 81870134), Shenzhen Science and Technology Foundation (JCYJ20190808163601776, JCYJ20200109113810154) and Shenzhen Key Laboratory Foundation (ZDSYS20200811143757022).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.686013/ full#supplementary-material

- Grunwald MR, Levis MJ. FLT3 Inhibitors for Acute Myeloid Leukemia: A Review of Their Efficacy and Mechanisms of Resistance. *Int J Hematol* (2013) 97:683–94. doi: 10.1007/s12185-013-1334-8
- Elshoury A, Przespolewski A, Baron J, Wang ES. Advancing Treatment of Acute Myeloid Leukemia: The Future of FLT3 Inhibitors. *Expert Rev Anticancer Ther* (2019) 19:273–86. doi: 10.1080/14737140.2019.157367
- Knapper S, Russell N, Gilkes A, Hills RK, Gale RE, Cavenagh JD, et al. A Randomized Assessment of Adding the Kinase Inhibitor Lestaurtinib to First-Line Chemotherapy for FLT3-mutated Aml. *Blood* (2017) 129:1143–54. doi: 10.1182/blood-2016-07-730648
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. J Clin Epidemiol (2009) 62:e1-e34. doi: 10.1371/ journal.pmed.1000100
- Stang A. Critical Evaluation of the Newcastle-Ottawa Scale for the Assessment of the Quality of Nonrandomized Studies in Meta-Analyses. *Eur J Epidemiol* (2010) 25:603–5. doi: 10.1007/s10654-010-9491-z
- Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions. Chichester (UK): John Wiley & Sons. (2019).
- Begg CB, Mazumdar M. Operating Characteristics of a Rank Correlation Test for Publication Bias. *Biometrics*. (1994) 50:1088–101. doi: 10.2307/2533446
- Egger M, Smith GD, Schneider M, Minder C. Bias in Meta-Analysis Detected by a Simple, Graphical Test. Br Med J (1997) 315:629–34. doi: 10.1136/ bmj.315.7109.629
- Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised Recommendations of the International Working Group for

Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. *J Clin Oncol* (2003) 21:4642–9. doi: 10.1200/JCO.2003.04.036

- Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical Methods for Incorporating Summary Time-to-Event Data Into Meta-Analysis. *Trials* (2007) 8:1–16. doi: 10.1186/1745-6215-8-16
- Magnan S, Zarychanski R, Pilote L, Bernier L, Shemilt M, Vigneault E, et al. Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. *JAMA Oncol* (2015) 1 (9):1261–9. doi: 10.1001/jamaoncol.2015.2895
- Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE Guidelines: 7. Rating the Quality of Evidence-Inconsistency. J Clin Epidemiol (2011) 64(12):1294–302. doi: 10.1016/j.jclinepi.2011.03.017
- Dias S, Welton NJ, Caldwell D, Ades AE. Checking Consistency in Mixed Treatment Comparison Meta-Analysis. *Stat Med* (2010) 29:932–44. doi: 10.1002/sim.3767
- Serve H, Krug U, Wagner R, Sauerland MC, Heinecke A, Brunnberg U, et al. Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial. J Clin Oncol (2013) 31:3110–8. doi: 10.1200/ JCO.2012.46.4990
- Xuan L, Wang Y, Huang F, Jiang E, Deng L, Wu B, et al. Effect of Sorafenib on the Outcomes of Patients With FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. *Cancer.* (2018) 124:1954–63. doi: 10.1002/cncr.31295
- Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, et al. Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for Patients With FLT3 Mutant AML in First Relapse. *Blood* (2011) 117:3294– 301. doi: 10.1182/blood-2010-08-301796
- Zhang W, Konopleva M, Ruvolo V, McQueen T, Evans R, Bornmann W, et al. Sorafenib Induces Apoptosis of AML Cells *Via* Bim-mediated Activation of the Intrinsic Apoptotic Pathway. *Leukemia* (2008) 22:808–18. doi: 10.1038/ sj.leu.2405098
- Röllig C, Thiede C, Gramatzki M, Aulitzky W, Bodenstein H, Bornhauser M, et al. A Novel Prognostic Model in Elderly Patients With Acute Myeloid Leukemia: Results of 909 Patients Entered Into the Prospective AML96 Trial. *Blood* (2010) 116:971–8. doi: 10.1182/blood-2010-01-267302
- 26. Bazarbachi A, Bug G, Baron F, Brissot E, Ciceri F, Abou Dalle I, et al. Clinical Practice Recommendation on Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia Patients With FLT3-Internal Tandem Duplication: A Position Statement From the Acute Leukemia Working Party of the

European Society for Blood and Marrow Transplantation. *Haematologica* (2020) 105:1507-16. doi: 10.3324/haematol.2019.243410

- 27. Schiller GJ, Tuttle P, Desai P. Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD-positive Acute Myelogenous Leukemia: The Role for Flt3 Tyrosine Kinase Inhibitors Post-Transplantation. *Biol Blood Marrow Transplant* (2016) 22:982–90. doi: 10.1016/j.bbmt.2016.01.013
- Xuan L, Wang Y, Huang F, Fan Z, Xu Y, Sun J, et al. Sorafenib Maintenance in Patients With FLT3-ITD Acute Myeloid Leukaemia Undergoing Allogeneic Haematopoietic Stem-Cell Transplantation: An Open-Label, Multicentre, Randomised Phase 3 Trial. *Lancet Oncol* (2020) 21:1201–12. doi: 10.1016/ S1470-2045(20)30455-1
- Maziarz RTT, Patnaik MM, Scott BL, Mohan SR, Deol A, Rowley SD, et al. Radius: A Phase 2 Randomized Trial Investigating Standard of Care ±Midostaurin After Allogeneic Stem Cell Transplant in FLT3-ITD-mutated Aml. *Blood* (2018) 132(Supplement 1):662. doi: 10.1182/blood-2018-99-113582
- 30. Bazarbachi A, Labopin M, Battipaglia G, Djabali A, Passweg J, Socié G, et al. Sorafenib Improves Survival of FLT3-mutated Acute Myeloid Leukemia in Relapse After Allogeneic Stem Cell Transplantation: A Report of the EBMT Acute Leukemia Working Party. *Haematologica* (2019) 104:e398–401. doi: 10.3324/haematol.2018.211615
- 31. Xuan L, Wang Y, Chen J, Jiang E, Gao L, Wu B, et al. Sorafenib Therapy Is Associated With Improved Outcomes for FMS-Like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant* (2019) 25:1674–81. doi: 10.1016/j.bbmt.2019.04.018
- Pratz KW, Sato T, Murphy KM, Stine A, Rajkhowa T, Levis M. FLT3-Mutant Allelic Burden and Clinical Status are Predictive of Response to FLT3 Inhibitors in AML. *Blood* (2010) 115:1425–32. doi: 10.1182/blood-2009-09-242859

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Xu, He and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.